<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003223.pub2" GROUP_ID="SYMPT" ID="428801013009355132" MERGED_FROM="" MODIFIED="2015-07-07 16:15:31 +0100" MODIFIED_BY="[Empty name]" REVIEW_NO="28" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.2">
<COVER_SHEET MODIFIED="2015-07-07 16:15:31 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Calcitonin for metastatic bone pain</TITLE>
<CONTACT>
<PERSON ID="15772" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria José</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Martinez-Zapata</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Researcher</POSITION>
<EMAIL_1>mmartinezz@santpau.cat</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT>
<ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION>
<ADDRESS_1>Sant Antoni M. Claret 171</ADDRESS_1>
<ADDRESS_2>Casa de Convalescència</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION>Catalonia</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 93 553 78 08</PHONE_1>
<PHONE_2>+34 93 553 78 14</PHONE_2>
<FAX_1>+34 93 553 78 09</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-07-07 16:15:01 +0100" MODIFIED_BY="Anna Hobson">
<PERSON ID="15772" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria José</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Martinez-Zapata</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Researcher</POSITION>
<EMAIL_1>mmartinezz@santpau.cat</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT>
<ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION>
<ADDRESS_1>Sant Antoni M. Claret 171</ADDRESS_1>
<ADDRESS_2>Casa de Convalescència</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION>Catalonia</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 93 553 78 08</PHONE_1>
<PHONE_2>+34 93 553 78 14</PHONE_2>
<FAX_1>+34 93 553 78 09</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="AAD7845D82E26AA20130726F85E76FD4" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Marta</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Roqué i Figuls</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>mroque@santpau.cat</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT>
<ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION>
<ADDRESS_1>Sant Antoni Maria Claret 171</ADDRESS_1>
<ADDRESS_2>Edifici Casa de Convalescència</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION>Catalunya</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 935 537 814</PHONE_1>
<PHONE_2>+34 935 537 808</PHONE_2>
<FAX_1>+34 935 537 809</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15610" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Elena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Català</LAST_NAME>
<SUFFIX/>
<POSITION>Anesthesiologist</POSITION>
<EMAIL_1>ecatala@hsp.santpau.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service of Anesthesiology</DEPARTMENT>
<ORGANISATION>Hospital de la Santa Creu i Sant Pau</ORGANISATION>
<ADDRESS_1>Casa de Convalescencia</ADDRESS_1>
<ADDRESS_2>Sant Antoni M Claret 171</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="39690137865522826803111005123724" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Yuani</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Roman</LAST_NAME>
<SUFFIX/>
<POSITION>Collaborator</POSITION>
<EMAIL_1>yuanniroman@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+34 655933341</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre</DEPARTMENT>
<ORGANISATION>Institute of Biomedical Research Sant Pau (IIB Sant Pau), Barcelona</ORGANISATION>
<ADDRESS_1>Sant Antoni Ma Claret, 171</ADDRESS_1>
<ADDRESS_2/>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION>Barcelona</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 935537808</PHONE_1>
<PHONE_2/>
<FAX_1>+34 935537809</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="62B6005E82E26AA200991D56D1FC64D0" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pablo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Alonso-Coello</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Researcher</POSITION>
<EMAIL_1>palonso@santpau.cat</EMAIL_1>
<EMAIL_2>alonsocoello@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre</DEPARTMENT>
<ORGANISATION>Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2>Sant Antoni Maria Claret 171 - Edifici Casa de Convalescencia</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION>Catalunya</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 932 919 527</PHONE_1>
<PHONE_2/>
<FAX_1>+34 932 919 525</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-07-07 16:15:01 +0100" MODIFIED_BY="Anna Hobson">
<UP_TO_DATE>
<DATE DAY="24" MONTH="2" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="2" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="6" MONTH="7" YEAR="2020"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2015-07-07 16:15:31 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-07-07 16:15:31 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="7" YEAR="2015"/>
<DESCRIPTION>
<P>This review will be assessed for further updating in 2020.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-07-07 16:15:13 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-07-07 16:15:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="2" YEAR="2015"/>
<DESCRIPTION>
<P>Searches updated and Summary of findings table added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-07-07 16:15:13 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="2" YEAR="2015"/>
<DESCRIPTION>
<P>No new studies were identified for inclusion; one additional study was excluded. The conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-03-02 14:45:29 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-06-27 19:39:04 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="29" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>The update of this systematic review did not change the conclusions or add any new included studies to the previously published review. The bibliographic searches retrieved a total of 11 studies likely to be included in the review. Following assessment, we excluded nine studies as they did not meet the inclusion criteria. Three of the nine excluded studies were newly identified studies that we then excluded because they were not controlled (<LINK REF="STD-Tsavaris-2006" TYPE="STUDY">Tsavaris 2006</LINK>) or had no placebo (<LINK REF="STD-Beaufort-1984" TYPE="STUDY">Beaufort 1984</LINK>; <LINK REF="STD-Gennari-1989" TYPE="STUDY">Gennari 1989</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-11-21 13:01:00 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-12 17:11:55 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="24" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-01-09 09:07:36 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="23" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>This is an update of the review originally published in Issue 3, 2003 of <I>The Cochrane Library</I>. Two new excluded studies were identified but no new studies were included and therefore there was no change to the original conclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-06-28 14:09:16 +0100" MODIFIED_BY="Denise M Mitchell">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-06-28 14:09:16 +0100" MODIFIED_BY="Denise M Mitchell">
<SOURCE MODIFIED="2011-10-25 22:33:55 +0100" MODIFIED_BY="[Empty name]">
<NAME>Agencia Evaluación Tecnologías Sanitarias, Fondo de Investigaciones Sanitarias FIS. Instituto de Salud Carlos III. Subdirección General de Investigación Sanitaria. (01/A060)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-10-25 22:34:08 +0100" MODIFIED_BY="[Empty name]">
<NAME>Instituto de Salud Carlos III. Subdirección General de Investigación Sanitaria. Ministerio de Salud y Consumo. (01/F070)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-01-09 09:03:54 +0000" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Center. IIB Sant Pau</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>The first version was funded by the institutions above mentioned. The updates of the review were funded by the Iberoamerican Cochrane Center, IIB Sant Pau</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2015-06-28 14:09:16 +0100" MODIFIED_BY="Denise M Mitchell">
<NAME>Pablo Alonso-Coello is supported by a Miguel Servet investigator contract from the Instituto de Salud Carlos III (CP09/00137)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-07-03 14:01:53 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-07-03 13:57:23 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-27 11:27:57 +0000" MODIFIED_BY="Jessica Thomas">Calcitonin used to treat metastatic bone pain</TITLE>
<SUMMARY_BODY MODIFIED="2015-07-03 13:57:23 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;No lo pondr&amp;#237;a en el plain language summary. Lo quitar&amp;#237;a pues ya dices que la evidencia no apoya su uso...&lt;/p&gt;&lt;p&gt;Si hablar&amp;#225;s de esto habr&amp;#237;a en t&amp;#233;rminos de confianza en los resultados...&lt;/p&gt;" NOTES_MODIFIED="2015-07-03 13:57:23 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>People who have cancer which has spread to their bones and the nerves adjacent to the bones often suffer severe pain. There are several treatments to help relieve this pain: radiotherapy, analgesic drugs (pain killers) such as opioids, and bone-modulating drugs such as bisphosphonates and calcitonin. Calcitonin has the potential to relieve pain and maintain bone strength, thus reducing the risk of broken bones. This review looked at the effectiveness of calcitonin for controlling pain from bone metastases. However, only two studies were found with very low quality evidence to support the use of calcitonin for patients suffering from bone pain. We updated the review in 2015 and did not find any more studies. There were slightly more side effects for the patients given calcitonin. Unless new studies provide additional relevant information about this treatment, other therapeutic approaches should be considered.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-07-03 13:52:09 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-07-03 13:52:09 +0100" MODIFIED_BY="[Empty name]">
<P>Pain is the most frequent symptom experienced by cancer patients, its intensity dependent on the site of the tumour. Tumours that compromise bone or nervous structures due to the bone destruction process are the most painful. There are several treatments to deal with pain (and other symptoms) caused by bone metastases. The hormone calcitonin has the potential to relieve pain and also retain bone density, thus reducing the risk of fractures. This review is an update of a previously published review in the<I> Cochrane Library</I> (2003, Issue 3) which was also updated in 2006 (Issue 3) and in 2011 (Issue 9).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-04-10 22:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>The main objective of the review is to determine the effectiveness of calcitonin to reduce metastatic bone pain in patients with painful bone metastases. Secondary objectives are to assess the benefits of calcitonin in reducing the incidence of bone complications (hypercalcemia, fractures and nervous compression) and improving patient survival, and to report any adverse effects of the treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-02-26 10:29:01 +0000" MODIFIED_BY="[Empty name]">
<P>We updated the electronic searches in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE up to February 2015. We also searched registers of clinical trials in progress up to February 2015.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-01-08 12:36:50 +0000" MODIFIED_BY="[Empty name]">
<P>We included studies if they were randomised, double-blind clinical trials of patients with metastatic bone pain, treated with calcitonin, where the major outcome measure was pain, assessed at four weeks or longer.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-07-02 15:01:44 +0100" MODIFIED_BY="[Empty name]">
<P>Two independent review authors performed study selection and data extraction. Only two studies (90 participants) were eligible for inclusion in the review and therefore meta-analysis of the data was not possible. We performed intention-to-treat (ITT) analysis by imputing all missing values as adverse effects.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-04-10 22:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>The overall quality of the evidence was very low. In this update no new studies were identified for inclusion; one additional study was excluded. Of the two small included studies, one study showed a non-significant effect of calcitonin on the number of patients with complete pain relief (risk ratio (RR) 2.50; 95% confidence interval (CI) 0.55 to 11.41). The second study provided no evidence that calcitonin reduced analgesia consumption (RR 1.05; 95% CI 0.90 to 1.21) in patients with painful bone metastases. There was no evidence that calcitonin was effective in controlling complications due to bone metastases, for improving quality of life or for patients' survival. Although not statistically significant, a greater number of adverse effects were observed in the groups given calcitonin in the two included studies (RR 3.50; 95% CI 0.77 to 15.88).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-07-01 15:20:02 +0100" MODIFIED_BY="[Empty name]">
<P>Current available research evidence is of very low quality and there is a lack of evidence to support the use of calcitonin for managing bone pain from bone metastases. Since the last version of this review, we did not identify any additional studies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-07-03 13:59:45 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-07-03 13:52:23 +0100" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review originally published in the<I> Cochrane Library</I> in Issue 3, 2003 and updated in Issue 3, 2006 and Issue 9, 2011, on 'Calcitonin for metastatic bone pain'. Pain is the most frequent symptom of cancer patients, its intensity dependent on the site of the tumour (<LINK REF="REF-Portenoy-1989" TYPE="REFERENCE">Portenoy 1989</LINK>). Tumours that compromise bone or nervous structures are the most painful.</P>
<CONDITION MODIFIED="2015-02-16 08:52:10 +0000" MODIFIED_BY="[Empty name]">
<P>The incidence of malignant bone tumours is relatively low but the development of bone metastases in primary breast, lung, prostate and kidney tumours is common. A high proportion of patients diagnosed with malignant breast, lung and prostate tumours (80% to 85%) develop a bone metastasis (<LINK REF="REF-Nelson-1991" TYPE="REFERENCE">Nelson 1991</LINK>). Pain and functional disability occur in 45% to 75% of cases, whereas major complications will be observed in up to one-third of patients whose first relapse occurs in bone. Hypercalcaemia occurs in 10% to 15% of these patients and fractures in 10% to 20% (<LINK REF="REF-Body-2000" TYPE="REFERENCE">Body 2000</LINK>).</P>
<P>Pain arises as a result of bone destruction and, as more destruction ensues, the patient experiences more pain. Pain is also caused by periosteal narrowing due to tumour growth and cortical bone deformation. Radiculopathies, plexopathies and the shrinkage of spinal nerves due to tumour growth and fractures are frequent events in these patients. This situation makes both diagnosis and treatment more complicated, limiting the patient's mobility, confining them to bed rest and thereby weakening the patient and increasing the risk of thromboembolic disease, hypercalcaemia, atelectasis (failure of the normal expansion of part or all of the lung) and pneumonia (as a result of rib metastases).</P>
<P>It is too simplistic to explain bone pain on purely mechanistic grounds, as bone metastases are manifested through pain which can arise even before the injury is radiologically detected. The pain also occurs as a result of the release of substance P (neuropeptide), bradykinins, prostaglandins and other cytokines by the neoplastic cells, which lead to stimulation of C-type fibres within the bone (<LINK REF="REF-Paterson-2000" TYPE="REFERENCE">Paterson 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-01-08 12:42:36 +0000" MODIFIED_BY="[Empty name]">
<P>Several treatments are available to manage the pain caused by bone metastasis. Some are directed at the tumour itself and thus also treat the pain. Others specifically address the pain because pain-induced impairment can become more debilitating than the symptoms of the illness itself. Despite the availability of therapies, however, cancer-related pain continues to be under treated.</P>
<P>The therapeutic strategies for painful bone metastases are based on different mechanisms, for example:<BR/>
</P>
<UL>
<LI>base treatments or treatments directed towards oncological illness;</LI>
<LI>conventional analgesics, e.g. paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) with or without opioid;</LI>
<LI>radiotherapy for localised bone metastases;</LI>
<LI>specific drugs for bone pain that work on the bone tumour-induced alteration, e.g. bisphosphonates which inhibit osteoclastic activity and reduce bone resorption (<LINK REF="REF-Eisenberg-1994" TYPE="REFERENCE">Eisenberg 1994</LINK>), radioactive agents such as estronium-89 (<LINK REF="REF-Robinson-1995" TYPE="REFERENCE">Robinson 1995</LINK>) or calcitonin.</LI>
</UL>
</INTERVENTION>
<THEORY MODIFIED="2012-01-08 12:43:22 +0000" MODIFIED_BY="[Empty name]">
<P>Calcitonin is a hormone produced in the thyroid glands of some animals. It has a hypocalcaemic action that is due primarily to the inhibition of osteoclastic bone resorption, and secondarily by action on the kidneys that results in increased urinary excretion of calcium and phosphorus. Naturally occurring porcine calcitonin, synthetic salmon calcitonin (salcatonin) and synthetic human calcitonin are in clinical use. Salcatonin is the most potent and is used to control bone pain due to malignant neoplasms (<LINK REF="REF-Parfitt-1999" TYPE="REFERENCE">Parfitt 1999</LINK>). Salcatonin can cause nausea, vomiting and flushing, as well as unpleasant taste sensations, tingling in the hands and pain at the injection site. Some patients also experience an allergic reaction. In addition, salcatonin is immunogenic and antibodies may form; this may result in resistance to its pharmacological effects during long-term therapy (<LINK REF="REF-Grahame_x002d_Smith-2002" TYPE="REFERENCE">Grahame-Smith 2002</LINK>). Periodic monitoring of calcium and phosphorus is advisable during treatment (<LINK REF="REF-Lussier-2004" TYPE="REFERENCE">Lussier 2004</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-07-03 13:52:23 +0100" MODIFIED_BY="[Empty name]">
<P>Currently, the use of calcitonin for the relief of metastatic bone pain is not very common and little information is available about its use in this context. The most frequent routes of administration are subcutaneous and intranasal. The current analgesic dose by the intranasal route is 200 IU/day and the optimal dose by the subcutaneous route is not well defined (<LINK REF="REF-Lussier-2004" TYPE="REFERENCE">Lussier 2004</LINK>).</P>
<P>There is some evidence regarding the use of calcitonin to prevent bone fractures in post menopausal women with osteoporosis (<LINK REF="REF-Chesnut--2000" TYPE="REFERENCE">Chesnut 2000</LINK>; <LINK REF="REF-MacLean-2008" TYPE="REFERENCE">MacLean 2008</LINK>; <LINK REF="REF-Palmer-2007" TYPE="REFERENCE">Palmer 2007</LINK>), in kidney transplant recipients (Palmer 2007), to prevent corticosteroid-induced osteoporosis (<LINK REF="REF-Craney-2000" TYPE="REFERENCE">Craney 2000</LINK>), and to prevent hypercalcaemia in neoplastic processes (<LINK REF="REF-Matsumoto-2002" TYPE="REFERENCE">Matsumoto 2002</LINK>; <LINK REF="REF-Zojer-1999" TYPE="REFERENCE">Zojer 1999</LINK>), as a second-line treatment. However, there is unclear evidence on the effectiveness of calcitonin in treating phantom limb pain (<LINK REF="REF-Alviar-2011" TYPE="REFERENCE">Alviar 2011</LINK>) or complex regional pain syndrome (<LINK REF="REF-O_x0027_Connell--2013" TYPE="REFERENCE">O'Connell 2013</LINK>). It was therefore important that a systematic review of the data was undertaken to assess whether this treatment is effective to control bone pain and metastatic complications in patients with bone metastases. This review is an update of a previously published review in the <I>Cochrane Library </I>on this topic (<LINK REF="REF-Mart_x00ed_nez_x002d_Zapata-2006" TYPE="REFERENCE">Martínez-Zapata 2006</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-02-16 08:52:55 +0000" MODIFIED_BY="[Empty name]">
<P>The main objective of the review is to determine the effectiveness of calcitonin to reduce metastatic bone pain in patients with painful bone metastases. Secondary objectives are to assess the benefits of calcitonin in reducing the incidence of bone complications (hypercalcemia, fractures and nervous compression) and improving patient survival, and to report any adverse effects of the treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-07-03 13:59:45 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-07-03 13:59:45 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised, double-blind clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-01-08 12:44:59 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were adults (18 years old or more), men or women, with bone metastatic pain caused by any primary tumour, diagnosed by computed tomography, bone gammagraphy, nuclear magnetic resonance or other radiographic process.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-01-08 12:45:59 +0000" MODIFIED_BY="Jessica Thomas">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<UL>
<LI>Calcitonin plus a rescue medication versus placebo plus a rescue medication.</LI>
<LI>Any comparison between different models and intervention doses of interest.</LI>
<LI>The use of steroids or analgesic radiotherapy were accepted if administration was equal in each treatment arm.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<UL>
<LI>We excluded studies where bisphosphonates were administered before participants were randomised to different treatment groups from the study.</LI>
<LI>We excluded studies in which the efficacy of calcitonin in treating pain from bone metastases was measured over a short period (less than four weeks), considering only studies with a minimum follow-up.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-07-03 13:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>We collected data on the following outcome measures.<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-07-03 13:58:46 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Complete pain relief: percentage of patients with complete relief at <B>
<I>&#8805; </I>
</B>4 weeks follow-up.</LI>
<LI>Less or equal analgesia consumption.</LI>
<LI>Percentage of patients with less or equal analgesia consumption at <B>
<I>&#8805;</I>
</B>4 weeks follow-up.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-07-03 13:59:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Pain: intensity of pain measured by a standardised scale (e.g. analogical visual scale) at baseline, 4 weeks, 6 months, 9 months and 12 months.</LI>
<LI>Partial pain relief:percentage of patients' partial reduction of pain, defined as a reduction greater or equal to 50% from baseline.</LI>
<LI>Rescue medication at baseline and post intervention: percentage of patients with rescue medication.</LI>
<LI>Length of time of improvement.</LI>
<LI>Bone metastases complications: percentage of patients with bone metastases complications (hypercalcaemia, bone fracture, nerve root and bone marrow compression).</LI>
<LI>Quality of life measured by a standardised questionnaire.</LI>
<LI>Hospitalisation: percentage of patients with hospitalisation due to adverse effects.</LI>
<LI>Adverse effects: percentage of patients with adverse effects.</LI>
</UL>
<P>We did not collect subjective evaluations of pain rated by physicians, nurses or carers, only those rated by the patient.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-07-03 13:52:35 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-07-03 13:52:35 +0100" MODIFIED_BY="[Empty name]">
<P>This review is an update of a review previously published in the<I> Cochrane Library</I> in 2003 (<LINK REF="REF-Martinez_x002d_Zapata-2003" TYPE="REFERENCE">Martinez-Zapata 2003</LINK>), 2006 (<LINK REF="REF-Mart_x00ed_nez_x002d_Zapata-2006" TYPE="REFERENCE">Martínez-Zapata 2006</LINK>) and 2011. The last update was conducted in 2011, with no changes in the review or its citation.</P>
<P>In this update we searched for randomised controlled clinical trials (RCTs) related to this review electronically using:</P>
<UL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (the<I> Cochrane Library</I> 2015, Issue 1);</LI>
<LI>MEDLINE (1966 to week 4 February 2015);</LI>
<LI>EMBASE (1974 to week 4 February 2015).</LI>
</UL>
<P>We combined the general strategies to identify RCTs with specific search commands to identify trials of calcitonin and metastatic bone pain. The MEDLINE search strategy is detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; the details of the other search strategies are included in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>We searched the clinical trials database held by the Cochrane Cancer Network (where the results of handsearching relevant journals and other literature worldwide are collated), as well as the Cochrane Pain, Palliative and Supportive Care (PaPaS) Group Specialised Register. For the current update we did not search the PaPaS Specialised Register as it is no longer updated.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-03-11 12:53:20 +0000" MODIFIED_BY="[Empty name]">
<P>We sought ongoing trials from the following databases searching for "calcitonin" AND "all recruitment status" (from 1/1/2006 until 16/2/15):<BR/>
</P>
<UL>
<LI>WHO International Clinical Trials Registry Platform (<A HREF="http://www.who.int/ictrp/en/">http://www.who.int/ictrp/en/</A>)</LI>
</UL>
<P>We reviewed identified systematic reviews, meta-analyses and reference lists of identified RCTs in order to identify further RCTs. We undertook no additional handsearching of journals. There was no language restriction in the search strategy and selection of papers.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-07-03 13:45:55 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-01-05 23:25:43 +0000" MODIFIED_BY="[Empty name]">
<P>The authors critically appraised the studies identified through the search strategy for inclusion in the systematic review. Two independent review authors (MM and YR) assessed each study in an open fashion: we undertook no blinding of authors, institutions or source of publication of the study. There were no major discrepancies between the review authors in the selection of studies.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-02-16 08:56:36 +0000" MODIFIED_BY="[Empty name]">
<P>We designed a data collection form to record:<BR/>
</P>
<UL>
<LI>the characteristics of the study participants;</LI>
<LI>details of the intervention and the comparison groups;</LI>
<LI>the results from each participant subgroup;</LI>
<LI>risk of bias.</LI>
</UL>
<P>With regard to studies with a cross-over design, we only collected and analysed data corresponding to the first period of treatment.</P>
<P>Two independent review authors sorted the data and completed a standard spreadsheet form designed for that purpose. If the information provided in the studies was incomplete, we contacted the study authors to provide the required data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-07-03 13:37:50 +0100" MODIFIED_BY="[Empty name]">
<P>In this update two independent review authors (EC and YR) assessed the risk of bias. Where there was disagreement, MM participated in the final decision.</P>
<P>We based our 'Risk of bias' assessment on the proposals described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We examined the adequacy of the method used to generate the allocation sequence, the allocation concealment and the level of blinding (clinician, participant or outcome assessor). We further examined the presence of incomplete outcome data and selective reporting.</P>
<P>We classified each study to be at high, unclear or low risk of bias. We described the reason for each judgement from details provided in the studies or from data sought from the original authors. We considered a study to be at low risk of bias when it concealed allocation and blinded participants and outcome assessors, if it reported complete outcome data and there was no selective reporting or other biases. If one or more of these key domains were not met, we considered the study to be at a high risk of bias. If one or more of these key domains were unclear, we considered the study as 'unclear' with respect to risk of bias (see table 8.7a of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>, <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We also evaluated the quality of the evidence with the GRADE (Grades of recommendation, Assessment, Development and Evaluation) system and developed a 'Summary of findings' table (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). The quality (certainty) of the evidence is rated as high, moderate, low or very low and takes into account several components (risk of bias, consistency, directness, precision and publication bias).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-07-03 13:41:52 +0100" MODIFIED_BY="[Empty name]">
<P>We estimated the effect of bone pain treatment by calculating the risk ratio (RR) and standardised mean difference (SMD), with their corresponding confidence intervals (CIs). If the results had been statistically significant, we would have computed clinical effect measures such as the number needed to treat to benefit one patient (NNTB) or the number needed to treat to harm one patient (NNTH).</P>
<P>We calculated the global estimate of the effect of each variable by conducting a meta-analysis of single effect measures of the study. We used the Mantel-Haezsel (M-H) method (<LINK REF="REF-Mantel-1959" TYPE="REFERENCE">Mantel 1959</LINK>) for dichotomised variables and the inverse of variance for continuous variables.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-10-25 22:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-01-08 12:55:18 +0000" MODIFIED_BY="[Empty name]">
<P>We performed an intention-to-treat (ITT) analysis, analysing each participant in their corresponding randomised treatment group, independent of either completion or withdrawal from the study. For dichotomous variables, we imputed missing values due to drop-outs or withdrawals by categorising the participants as non-respondents. In the analysis of adverse effects, we considered all participants who withdrew from the study as having suffered an adverse effect, or not to have experienced a positive treatment effect. For continuous variables, we analysed data as provided by the study authors, either per protocol or per ITT.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-07-03 13:45:55 +0100" MODIFIED_BY="[Empty name]">
<P>We quantified the impact of statistical heterogeneity using the I<SUP>2</SUP> statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If percentage of heterogeneity (I<SUP>2</SUP>) was less than 50% we applied a fixed-effect model, and where it was between 50% and 75% we applied a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). Where heterogeneity was significant (<U>&gt;</U> 75%) we investigated possible causes of the heterogeneity by exploring the impact of participants' characteristics and the risk of bias of the studies.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-01-08 12:57:44 +0000" MODIFIED_BY="[Empty name]">
<P>We checked if the results of all variables specified in the methods of the included studies were reported.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-04-10 15:38:27 +0100" MODIFIED_BY="[Empty name]">
<P>When we considered the included studies to be comparable enough and to provide sufficiently similar methods to measure the outcomes, we summarised their findings by pooling the results using a fixed-effect model using Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). If there were doubts about the similarity of participant characteristics or the methods used to measure the outcomes we pooled the data using a random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-11-21 14:04:01 +0000" MODIFIED_BY="[Empty name]">
<P>It was not possible to perform subgroup analyses by primary tumour location, stage and route of treatment due to the low number of studies included in the review.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-07-02 16:04:52 +0100" MODIFIED_BY="[Empty name]">
<P>Only two studies met the criteria for inclusion in this review, therefore it was not possible to perform a sensitivity analysis to assess how robust the estimate of the global effect was regarding, per protocol analysis, published studies, risk of bias of studies and imputation strategies.</P>
<P>Whereas in the main analyses we assumed all participants withdrawing from studies to present an absence of a positive effect or an adverse effect, for the sensitivity analyses we repeated imputation based on the assumption that the participants who withdrew presented adverse effects in the same proportion as the participants observed in the control group.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-07-03 13:45:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-07-02 15:10:48 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-07-02 15:10:26 +0100" MODIFIED_BY="[Empty name]">
<P>For the previous version of this review bibliographic searches retrieved a total of 11 studies likely to be included in the review. Following assessment, we excluded nine studies. We included two randomised, double-blind clinical trials with a total of 90 women with breast cancer and pain from bone metastasis. There were no ongoing clinical trials. For this update the search identified seven records that did not fulfil the inclusion criteria of this review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-04-10 22:51:34 +0100" MODIFIED_BY="[Empty name]">
<P>The two studies that met the inclusion criteria were, as for the last update, <LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK> and <LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK>. We found no new studies which impacted on the original outcome of this systematic review.</P>
<P>
<LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK> compared calcitonin (100 IU administered subcutaneously each day for 28 days) versus placebo administered to a group of 40 women with breast cancer and pain from bone metastasis. The analgesic effect of calcitonin was assessed through analgesic consumption, functional capacity, pain duration and patient pain self assessment. Participants were followed for one month. There were two drop-outs in the intervention group.</P>
<P>
<LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK> compared calcitonin (100 IU administered subcutaneously each day for three months) versus placebo in 50 women with breast cancer and painful bone metastases. Pain control was assessed over one year. There was one drop-out per treatment group. Participants were followed for up to 24 months. Although this study assessed both pain and use of analgesics, the study did not provide quantifiable data for pain reduction and allowed quantitative analysis of use of analgesics only.</P>
<P>A detailed description of the included studies can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-07-02 15:10:48 +0100" MODIFIED_BY="[Empty name]">
<P>In the present update the search identified seven studies. One study assessed denosumab for refractory hypercalcaemia of malignancy.Three studies assessed calcitonin for hypercalcemia, and one study for Paget's disease. Two studies assessed calcitonin for cancer pain, but one was not a clinical trial, and the other was a randomised clinical trial that compared pamidronate versus calcitonin without a placebo group (<LINK REF="STD-El-Wasseef--2012" TYPE="STUDY">El Wasseef 2012</LINK>). We excluded nine studies from the previous version of the review (<LINK REF="STD-Allan-1983" TYPE="STUDY">Allan 1983</LINK>; <LINK REF="STD-Beaufort-1984" TYPE="STUDY">Beaufort 1984</LINK>; <LINK REF="STD-Berrenssen-1985" TYPE="STUDY">Berrenssen 1985</LINK>; <LINK REF="STD-Gennari-1989" TYPE="STUDY">Gennari 1989</LINK>; <LINK REF="STD-Hindley-1982" TYPE="STUDY">Hindley 1982</LINK>; <LINK REF="STD-Kleibel-1984" TYPE="STUDY">Kleibel 1984</LINK>; <LINK REF="STD-Lepidini-1992" TYPE="STUDY">Lepidini 1992</LINK>; <LINK REF="STD-Serdenge_x00e7_ti-1986" TYPE="STUDY">Serdengeçti 1986</LINK>; <LINK REF="STD-Tsavaris-2006" TYPE="STUDY">Tsavaris 2006</LINK>) and one new study from the 2015 update (<LINK REF="STD-El-Wasseef--2012" TYPE="STUDY">El Wasseef 2012</LINK>)<I>.</I> The reasons for exclusion were as follows:</P>
<UL>
<LI>assessment of pain was performed less than four weeks after the treatment (<LINK REF="STD-Allan-1983" TYPE="STUDY">Allan 1983</LINK>; <LINK REF="STD-Beaufort-1984" TYPE="STUDY">Beaufort 1984</LINK>; <LINK REF="STD-Berrenssen-1985" TYPE="STUDY">Berrenssen 1985</LINK>; <LINK REF="STD-Gennari-1989" TYPE="STUDY">Gennari 1989</LINK>; <LINK REF="STD-Hindley-1982" TYPE="STUDY">Hindley 1982</LINK>; <LINK REF="STD-Kleibel-1984" TYPE="STUDY">Kleibel 1984</LINK>);</LI>
<LI>single-blind design (<LINK REF="STD-Serdenge_x00e7_ti-1986" TYPE="STUDY">Serdengeçti 1986</LINK>);</LI>
<LI>open study with no control group (<LINK REF="STD-Lepidini-1992" TYPE="STUDY">Lepidini 1992</LINK>; <LINK REF="STD-Tsavaris-2006" TYPE="STUDY">Tsavaris 2006</LINK>);</LI>
<LI>
<LINK REF="STD-Kleibel-1984" TYPE="STUDY">Kleibel 1984</LINK> was identified in the search strategy of the old version of this review and was ignored due to different inclusion criteria. In the present update the review authors have re-evaluated and excluded it because outcome assessment was less than one month after treatment. <LINK REF="STD-Berrenssen-1985" TYPE="STUDY">Berrenssen 1985</LINK> has also been identified as an excluded study in the update due to some changes in the design of the search strategy, in comparison with the previous review (outcome assessment less than one month after treatment);</LI>
<LI>there was no placebo group used in the study (<LINK REF="STD-Beaufort-1984" TYPE="STUDY">Beaufort 1984;</LINK> El Wasseef 2012; <LINK REF="STD-Gennari-1989" TYPE="STUDY">Gennari 1989</LINK>).</LI>
</UL>
<P>A detailed description of the excluded studies can be found in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-07-02 15:11:12 +0100" MODIFIED_BY="[Empty name]">
<P>The global risk of bias of the included studies was unclear (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), because some items did not specifically mention the method of randomisation and allocation concealment. One study (<LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK>) presented some imprecision defining the blinding of treatments.</P>
<ALLOCATION MODIFIED="2012-01-08 13:01:22 +0000" MODIFIED_BY="[Empty name]">
<P>The method to generate the sequence of randomisation and allocation concealment was not described in the two included studies (<LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK>; <LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-01-08 13:01:30 +0000" MODIFIED_BY="[Empty name]">
<P>In the <LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK> study, the placebo was a saline solution, but it is not specified if it was identical in appearance to calcitonin. Therefore, there is doubt around the blinding of participants and investigators.</P>
<P>In the <LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK> study, the concealment of treatment to the participant and investigators was well described.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-11-21 14:11:15 +0000" MODIFIED_BY="[Empty name]">
<P>Only two participants were lost in both included studies (<LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK>; <LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK>), therefore we excluded attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-07-02 15:11:12 +0100" MODIFIED_BY="[Empty name]">
<P>The results of all outcomes specified in the methods are presented in both <LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK> and <LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK> , therefore we excluded outcome reporting bias in these studies.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-07-03 13:45:12 +0100" MODIFIED_BY="[Empty name]">
<P>Only the two studies included in the original review (<LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK>; <LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK>) were included in this update; we included no new studies. The overall quality of the evidence was very low due to risk of bias and imprecision (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>The study by <LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK> provided data for the number of participants with complete pain relief . This was assessed one month after the start of treatment. More participants with complete pain relief were found in the group given calcitonin, but the difference did not reach a level of statistical significance (risk ratio (RR) 2.50; 95% confidence interval (CI) 0.55 to 11.41). Therefore, there was insufficient evidence that calcitonin is effective for complete pain relief.</P>
<P>
<LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK> was the only study that provided information on analgesic consumption during the trial period. Results showed that almost all the participants assigned to both calcitonin and placebo groups had equal analgesic consumption at baseline, or otherwise the use was similarly decreased (RR 1.05; 95% CI 0.90 to 1.21). These results should be interpreted along with the results for pain relief.</P>
<P>Unfortunately, there were no studies providing information on both variables. The two included studies did not provide sufficient evidence for the efficacy of calcitonin either for the treatment of pain or for complications from bone metastases to be quantitatively assessed. In addition, evidence for the effect of calcitonin on controlling complications due to bone metastases, improving quality of life and on patients' survival was not found.</P>
<P>Although not statistically significant, a greater number of participants with any adverse effect were observed in the groups given calcitonin in both included studies (RR 3.50; 95% CI 0.77 to 15.88) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The observed adverse effects were related to facial blushing in <LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK> and subcutaneous pain in <LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK>. In a sensitivity analysis, the results were minimally altered when we performed a per protocol analysis (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). An ITT analysis of the participants who withdrew presented adverse effects in the same proportion in both groups (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>The included studies did not report quantitative information about other outcomes like:</P>
<UL>
<LI>pain: intensity;</LI>
<LI>partial pain relief;</LI>
<LI>rescue medication;</LI>
<LI>length of time of improvement;</LI>
<LI>bone metastases complications;</LI>
<LI>quality of life;</LI>
<LI>hospitalisation due to adverse effects.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>Due to the small number of studies included in this review, and the features common to both, sensitivity analyses (by publication status or risk of bias) were unnecessary. In addition, because a low number of participants were lost to follow-up (two in each study) there was no difference when the data were analysed per protocol or by imputing missing data.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-07-03 13:52:42 +0100" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in the<I> Cochrane Library</I> (2011, Issue 9) on calcitonin for metastatic bone pain.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-07-03 13:40:20 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review was conducted to assess the efficacy of calcitonin in the control of pain due to bone metastases and bone complications. This updated review does not provide additional information on this treatment as no new relevant studies were included. All seven new studies identified in the search were excluded. Six of them were not related to the review and one of them was excluded with reasons.</P>
<P>This review, as in the previous reviews, includes two clinical trials involving a total of 90 participants who were treated for painful bone metastases with either a dose of 100 IU/day subcutaneous calcitonin or placebo. The follow-up and patient assessments were undertaken only in the short term.</P>
<P>Due to its antireabsorptive effects, by inhibiting osteoclasts and analgesic activity, it has been hypothesised that calcitonin has a likely benefit for bone pain. Only one study provided data about complete pain relief (<LINK REF="STD-Roth-1986" TYPE="STUDY">Roth 1986</LINK>). However, more participants with complete pain relief were found in the group given calcitonin; the difference with respect to the placebo group was not significant. The other study provided information on analgesic consumption during the trial period, but the results also showed no differences between groups (<LINK REF="STD-Blomqvist-1988" TYPE="STUDY">Blomqvist 1988</LINK>).</P>
<P>There was no evidence for the treatment of bone complications. Although not significant, the studies showed that calcitonin produced a greater number of adverse effects when compared with placebo. This result did not significantly change in the sensitivity analysis.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-11-21 14:21:49 +0000" MODIFIED_BY="[Empty name]">
<P>We have included all relevant studies that assessed calcitonin to treat metastatic bone pain. The small number of participants in the included studies assessing the efficacy of calcitonin may explain the non-conclusive results. The conclusions cannot be considered reliable and are susceptible to change in the future after publication of new reports that may provide further information. Moreover, the low number of participants that were included in the review led to a lack of power to detect small but significant changes of the intervention.</P>
<P>Only two studies in women with breast cancer and pain from bone metastasis were included. Therefore, there is a lack of evidence in men.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-04-10 18:38:22 +0100" MODIFIED_BY="[Empty name]">
<P>In general, the quality of evidence was very low due to risk of bias and the imprecision of the included studies. Although the two included studies were defined as randomised and double-blinded, there was a lack of description of randomisation generation and allocation concealment. One study did not describe the blinding of participants in enough depth. It was possible that there was reporting bias due to the publication years of the studies, because the requirements for conducting a study may have been less rigorous than they are today.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-01-08 13:08:49 +0000" MODIFIED_BY="[Empty name]">
<P>We identified a low number of studies despite an exhaustive bibliographic search and after establishing contact with authors of identified studies to provide information on further studies. Similarly, we applied no restrictions on status or language of publication.</P>
<P>In order to reduce the impact of attrition bias, we determined the number of losses to follow-up and their distribution per treatment group in the two included studies. This allowed an intention-to-treat (ITT) analysis and the exploration of the impact that losses to follow-up have on effect estimates. Due to the characteristics of the two included studies and the short follow-up period, losses were kept to a minimum and therefore no modifications to the analyses were necessary.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-07-02 15:12:49 +0100" MODIFIED_BY="[Empty name]">
<P>Pain relief must be the first objective in the treatment of bone metastases to improve the quality of life of patients. There are different treatment levels for achieving relief from pain, which normally start with an analgesic (paracetamol (acetaminophen)) or a non-steroidal anti-inflammatory drug (NSAID), and continue with low-potency opioids and then with another more powerful opioid (e.g. morphine). Frequently this drug sequence fails for a variety of reasons and often because the drugs are not prescribed at the highest therapeutic doses. When pain is not controlled with these options there are alternative treatments such as radiotherapy, radionucleotides, bisphosphonates or calcitonin.</P>
<P>Radiotherapy is commonly used to provide pain relief for localised painful bone metastases (<LINK REF="REF-Hoskin-1995" TYPE="REFERENCE">Hoskin 1995</LINK>; <LINK REF="REF-Sze-2002" TYPE="REFERENCE">Sze 2002</LINK>). About 75% of patients achieve pain relief and half of those stay free from pain (<LINK REF="REF-Jacox-1994" TYPE="REFERENCE">Jacox 1994</LINK>). However, when there are multiple bone metastases, systemic treatments such as bisphosphonates, radionucleotides and calcitonin with different evidence levels for efficacy may be necessary.</P>
<P>This review constitutes a contribution to the available scientific evidence on the use of calcitonin in this field, because we have not identified any systematic review that assesses calcitonin for metastatic bone pain. Nevertheless, due to the lack of primary studies, strong conclusions on the efficacy of calcitonin cannot be drawn.</P>
<P>Some systematic reviews of bisphosphonates (<LINK REF="REF-Wong-2002" TYPE="REFERENCE">Wong 2002</LINK>; <LINK REF="REF-Wong-2012" TYPE="REFERENCE">Wong 2012</LINK>; <LINK REF="REF-Yuen-2006" TYPE="REFERENCE">Yuen 2006</LINK>) have shown some evidence to indicate the efficacy of bisphosphonates for this indication, and also radionucleotides (<LINK REF="REF-Roqu_x00e9_-2011" TYPE="REFERENCE">Roqué 2011</LINK>). Based on the limited results of this review on the efficacy of calcitonin in relieving cancer-related bone pain, consideration should be given to different therapeutic approaches when making decisions on the management of pain from bone metastases.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-07-02 15:12:55 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-07-02 15:12:55 +0100" MODIFIED_BY="[Empty name]">
<P>There is very low quality evidence from two small studies on the effect of calcitonin on pain control and its associated adverse effects. There is a lack of evidence to support clinicians' use of calcitonin to control patients' pain from bone metastases. No additional studies were included in the present update. Until new studies provide additional information on this treatment, other therapeutic approaches should be considered.<I>
<BR/>
</I>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-05-01 11:34:14 +0100" MODIFIED_BY="[Empty name]">
<P>Calcitonin has been assessed in studies with small sample sizes, risk of bias and short-term evaluations. More double-blind, parallel clinical trials using long-term evaluations are needed. Future clinical trials should use realistic sample size calculations to evaluate the efficacy of calcitonin better, including adequate estimations of the number of participants likely to be lost to follow-up. This is the only way to guarantee a minimum level of quality, significance and power to demonstrate the actual efficacy of interventions.</P>
<P>Alternatively, the variables studied should be confined to reduction/absence of pain, adverse effects and quality of life. Possible complications of bone metastases, such as hypercalcemia, bone fractures or radicular compression, should also be quantified.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-05-08 12:40:34 +0100" MODIFIED_BY="[Empty name]">
<P>To Dr Suheyla Serdengeçti for replying to our requests for clarification, to Ms Miren Fernández for performing the bibliographic searches and to Dr Garcia Jl and Dr Ferrandiz for providing their clinical experience in the first version. To Sylvia Bickley for performing the searches for the previous update version. To Jane Hayes (Trials Search Co-ordinator of the previous version) and Joanne Abbott (Trials Search Co-ordinator of the present version of this review) for performing the bibliographic searches.</P>
<P>Cochrane Review Group funding acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service (NHS) or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-04-10 22:54:15 +0100" MODIFIED_BY="[Empty name]">
<P>Dr. Martinez has no relevant conflicts of interest to declare.</P>
<P>Dr. Roqué has no relevant conflicts of interest to declare.</P>
<P>Dr. Roman has no relevant conflicts of interest to declare.</P>
<P>Dr. Català has no relevant conflicts of interest to declare.</P>
<P>Dr. Pablo Alonso-Coello is funded by a Miguel Servet research contract from the Instituto de Salud Carlos III (CP09/00137).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-07-02 15:13:04 +0100" MODIFIED_BY="[Empty name]">
<P>All authors contributed to the interpretation of data, and commented on the final text and gave their final approval.</P>
<P>Dr. Martinez and Dr. Roqué were responsible for the conception and design of the study.</P>
<P>Dr. Martinez, Dr. Roqué and Dr. Alonso-Coello contributed to the analysis and interpretation of data.</P>
<P>Dr. Martinez was responsible for the data extraction process and the day-to-day work of the review.</P>
<P>Dr. Roman performed duplicate data extraction. Dr. Alonso-Coello revised the manuscript and collaborated on methodological aspects. Dr. Roqué revised the statistical and methodological aspects of the review and revised the manuscript. Dr. Català performed duplicate data extraction and provided clinical experience and insight on the protocol and review reports.</P>
<P>Dr. Martinez was responsible for co-ordinating the review update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-07-03 14:01:53 +0100" MODIFIED_BY="[Empty name]">
<P>In this 2015 updated review we have assessed the quality of evidence and added a 'Summary of findings' table using the GRADE approach. We have specified primary and secondary outcomes.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-07-03 13:36:12 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-05-08 12:32:39 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Blomqvist-1988" NAME="Blomqvist 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Blomqvist C, Elomaa I, Porkka L, Karonen SL, Lamberg-Allardt C. Evaluation of salmon calcitonin treatment in bone metastases from breast cancer--a controlled trial. Bone 1988; 9(1):45-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blomqvist C, Elomaa I, Porkka L, Karonen SL, Lamberg-Allardt C</AU>
<TI>Evaluation of salmon calcitonin treatment in bone metastases from breast cancer - a controlled trial</TI>
<SO>Bone</SO>
<YR>1988</YR>
<VL>9</VL>
<NO>1</NO>
<PG>45-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roth-1986" NAME="Roth 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Roth A, Kolaric K. Analgetic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study. Oncology 1986; 43(5):283-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roth A, Kolaric K</AU>
<TI>Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study</TI>
<SO>Oncology</SO>
<YR>1986</YR>
<VL>43</VL>
<NO>5</NO>
<PG>283-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-05-08 12:32:39 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Allan-1983" NAME="Allan 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Allan E. Calcitonin in the treatment of intractable pain from advanced malignancy. Pharmatherapeutica.1983;3(7):482-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allan E</AU>
<TI>Calcitonin in the treatment of intractable pain from advanced malignancy</TI>
<SO>Pharmatherapeutica</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>7</NO>
<PG>482-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beaufort-1984" MODIFIED="2011-11-21 13:49:58 +0000" MODIFIED_BY="[Empty name]" NAME="Beaufort 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-11-21 13:49:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beaufort F, Gölles M</AU>
<TI>Calcitonin in bone-metastasizing breast carcinoma. Results of a pilot study</TI>
<TO>Calcitonin beim skelettmetastasierten Mammakarzinom. Ergebnisse einer Pilot-Studie</TO>
<SO>Onkologie</SO>
<YR>1984</YR>
<VL>7</VL>
<NO>3</NO>
<PG>137-40</PG>
<IDENTIFIERS MODIFIED="2011-10-01 22:09:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-01 22:09:05 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PUBMED 6205336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-10-01 22:07:34 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berrenssen-1985" MODIFIED="2011-11-21 13:50:15 +0000" MODIFIED_BY="[Empty name]" NAME="Berrenssen 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-11-21 13:50:15 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Berressem P, Dambacher MA, and Schmidt G&lt;br&gt;Controlled trials of salmon calcitonin in patients with bone metastases. &amp;lt;ORIGINAL&amp;gt; KONTROLLIERTE WIRKUNGSPRUFUNGEN VON LACHS-CALCITONIN BEI PATIENTEN MIT KNOCHENMETASTASEN&lt;br&gt;THERAPIEWOCHE 1985 35 9 992-995&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-11-21 13:50:15 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berressem P, Dambacher MA, Schmidt G</AU>
<TI>Controlled trials of salmon calcitonin in patients with bone metastases</TI>
<TO>Kontrollierte wirkungsprufungen von lackhs-calcitonin bei patienten mit knochenmetatasen therapiewoche</TO>
<SO>Therapiewoche</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>9</NO>
<PG>992-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Wasseef--2012" MODIFIED="2015-05-08 12:32:39 +0100" MODIFIED_BY="[Empty name]" NAME="El Wasseef  2012" YEAR="2012">
<REFERENCE MODIFIED="2015-05-08 12:32:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>El Wasseef M, Ibrahim SE, Osman AM, El Kafrawy S</AU>
<TI>Pamidronate disodium versus calcitonin: a comparative study in the management of bone metastases in patients with breast cancer</TI>
<SO>Regional Anesthesia and Pain Medicine</SO>
<YR>2012</YR>
<VL>Conference abstract</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gennari-1989" MODIFIED="2011-11-21 13:49:14 +0000" MODIFIED_BY="[Empty name]" NAME="Gennari 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-11-21 13:49:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gennari C, Francini G, Chierichetti SM, Nami R, Gonelli S, Piolini M</AU>
<TI>Salmon calcitonin treatment in bone metastases</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1989</YR>
<VL>45</VL>
<NO>5</NO>
<PG>804-12</PG>
<IDENTIFIERS MODIFIED="2011-10-01 22:04:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-01 22:04:40 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1989138640"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-10-01 22:02:30 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hindley-1982" MODIFIED="2011-11-21 13:49:44 +0000" MODIFIED_BY="[Empty name]" NAME="Hindley 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-11-21 13:49:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hindley AC, Hill EB, Leyland MJ, Wiles AE. A double-blind controlled trial of salmon calcitonin in pain due to malignancy. Cancer Chemother Pharmacol. 1982;9(2):71-4.&lt;/p&gt;" NOTES_MODIFIED="2011-11-21 13:49:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hindley AC, Hill EB, Leyland MJ, Wiles AE</AU>
<TI>A double-blind controlled trial of salmon calcitonin in pain due to malignancy</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1982</YR>
<VL>9</VL>
<NO>2</NO>
<PG>71-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kleibel-1984" MODIFIED="2011-11-21 13:52:33 +0000" MODIFIED_BY="[Empty name]" NAME="Kleibel 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-11-21 13:52:33 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kleibel F and Schmidt G&lt;br&gt;[Salmon calcitonin in metastatic bone pain. Demonstration of acute analgesia in tumor patients]&lt;br&gt;Dtsch-Med-Wochenschr 1984 109 24 944-7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-11-21 13:52:33 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleibel F, Schmidt G</AU>
<TI>Salmon calcitonin in metastatic bone pain. Demonstration of acute analgesia in tumor patients</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1984</YR>
<VL>109</VL>
<NO>24</NO>
<PG>944-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepidini-1992" MODIFIED="2011-11-21 13:52:03 +0000" MODIFIED_BY="[Empty name]" NAME="Lepidini 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-11-21 13:52:03 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lepidini G et al. Terapia antalgica in corso di metastasi ossee: effetto dell&amp;#180;associazione calcitonina-HD e 6-metil prednisolone. Giornale italiano di ricerche cliniche e terapeutiche, 1992; 13: 123-127.&lt;/p&gt;" NOTES_MODIFIED="2011-11-21 13:52:03 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepidini G</AU>
<TI>Analgesic therapy in bone metastases: effect of association of calcitonin-HD and 6-methyl-prednisolone</TI>
<TO>Terapia antalgica in corso di metastasi ossee: effetto dell´associazione calcitonina-HD e 6-metil prednisolone</TO>
<SO>Giornale Italiano di Ricerche Cliniche e Terapeutiche</SO>
<YR>1992</YR>
<VL>13</VL>
<PG>123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Serdenge_x00e7_ti-1986" NAME="Serdengeçti 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Serdengecti S, Serdengecti K, Derman U, Berkarda B. Salmon calcitonin in the treatment of bone metastases. International Journal of Clinical Pharmacology Research 1986; 6(2):151-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serdengecti S, Serdengecti K, Derman U, Berkarda B</AU>
<TI>Salmon calcitonin in the treatment of bone metastases</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>2</NO>
<PG>151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsavaris-2006" MODIFIED="2011-11-21 13:35:30 +0000" MODIFIED_BY="[Empty name]" NAME="Tsavaris 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-11-21 13:35:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsavaris N, Kopterides P, Kosmas C, Vadiaka M, Dimitrakopoulos A, Scopelitis H, et al</AU>
<TI>Analgesic activity of high-dose intravenous calcitonin in cancer patients with bone metastases</TI>
<SO>Oncology Reports</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>4</NO>
<PG>871-5</PG>
<IDENTIFIERS MODIFIED="2011-10-02 22:32:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-02 22:32:55 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16969508"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-07-03 13:36:12 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-07-03 13:36:12 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alviar-2011" MODIFIED="2015-07-01 15:25:26 +0100" MODIFIED_BY="[Empty name]" NAME="Alviar 2011" TYPE="COCHRANE_REVIEW">
<AU>Alviar MJM, Hale T, Dungca M</AU>
<TI>Pharmacologic interventions for treating phantom limb pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2015-06-28 14:20:49 +0100" MODIFIED_BY="Denise M Mitchell">
<IDENTIFIER MODIFIED="2015-06-28 14:20:49 +0100" MODIFIED_BY="Denise M Mitchell" TYPE="DOI" VALUE="10.1002/14651858.CD006380.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Body-2000" MODIFIED="2011-10-25 22:31:30 +0100" MODIFIED_BY="[Empty name]" NAME="Body 2000" TYPE="JOURNAL_ARTICLE">
<AU>Body JJ</AU>
<TI>Bisphosphonates as chemotherapeutic agents</TI>
<SO>Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs</SO>
<YR>2000</YR>
<VL>2</VL>
<NO>2</NO>
<PG>155-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chesnut--2000" MODIFIED="2012-01-09 08:56:43 +0000" MODIFIED_BY="[Empty name]" NAME="Chesnut  2000" TYPE="JOURNAL_ARTICLE">
<AU>Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al</AU>
<TI>A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group</TI>
<SO>American Journal of Medicine</SO>
<YR>2000</YR>
<VL>109</VL>
<NO>4</NO>
<PG>267-76</PG>
<IDENTIFIERS MODIFIED="2011-10-03 14:47:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-03 14:47:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10996576."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Craney-2000" MODIFIED="2015-07-03 13:36:12 +0100" MODIFIED_BY="[Empty name]" NAME="Craney 2000" TYPE="COCHRANE_REVIEW">
<AU>Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, et al</AU>
<TI>Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-07-03 13:35:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-03 13:35:47 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001983"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-10-27 11:50:36 +0000" MODIFIED_BY="Jessica Thomas" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eisenberg-1994" MODIFIED="2012-01-09 08:57:27 +0000" MODIFIED_BY="Jessica Thomas" NAME="Eisenberg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC</AU>
<TI>Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1994</YR>
<VL>12</VL>
<PG>2756-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grahame_x002d_Smith-2002" MODIFIED="2012-01-09 08:57:44 +0000" MODIFIED_BY="[Empty name]" NAME="Grahame-Smith 2002" TYPE="BOOK">
<AU>Grahame-Smith DG, Aronson JK</AU>
<SO>Oxford Textbook of Clinical Pharmacology and Drug Therapy</SO>
<YR>2002</YR>
<EN>3rd</EN>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-06-28 13:27:05 +0100" MODIFIED_BY="Denise M Mitchell" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-07-02 15:06:48 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks, JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-07-02 15:06:58 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors).<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoskin-1995" NAME="Hoskin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hoskin P</AU>
<TI>Radiotherapy for bone pain</TI>
<SO>Pain</SO>
<YR>1995</YR>
<VL>63</VL>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacox-1994" MODIFIED="2008-10-27 11:50:54 +0000" MODIFIED_BY="Jessica Thomas" NAME="Jacox 1994" TYPE="BOOK_SECTION">
<AU>Jacox A, Carr DB, Payne R</AU>
<TI>Management of cancer pain</TI>
<SO>Clinical Practice Guideline No 9</SO>
<YR>1994</YR>
<PG>41-74</PG>
<PB>Agency for Health Care Policy and Research, US Department of Health and Human Services</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="AHCPR Publication No. 94-0592"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lussier-2004" MODIFIED="2012-01-09 08:58:05 +0000" MODIFIED_BY="[Empty name]" NAME="Lussier 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lussier D, Huskey AG, Portenoy RK</AU>
<TI>Adjuvant analgesics in cancer pain management</TI>
<SO>Oncologist</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>5</NO>
<PG>571-91</PG>
<IDENTIFIERS MODIFIED="2011-10-03 15:07:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-03 15:07:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15477643"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MacLean-2008" MODIFIED="2011-11-21 13:38:40 +0000" MODIFIED_BY="[Empty name]" NAME="MacLean 2008" TYPE="JOURNAL_ARTICLE">
<AU>MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al</AU>
<TI>Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis</TI>
<SO>Annals of Internal Medicine </SO>
<YR>2008</YR>
<VL>148</VL>
<NO>3</NO>
<PG>197-213</PG>
<IDENTIFIERS MODIFIED="2011-10-03 14:53:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-03 14:53:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18087050"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mantel-1959" MODIFIED="2015-07-02 17:03:23 +0100" MODIFIED_BY="[Empty name]" NAME="Mantel 1959" TYPE="JOURNAL_ARTICLE">
<AU>Mantel N, Haenszel W</AU>
<TI>Statistical aspects of the analysis of data from the retrospective analysis of disease</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1959</YR>
<VL>22</VL>
<NO>4</NO>
<PG>719&#8211;48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matsumoto-2002" MODIFIED="2011-11-21 13:39:32 +0000" MODIFIED_BY="[Empty name]" NAME="Matsumoto 2002" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto T, Nagata N, Horikoshi N, Adachi I, Ohashi Y, Ogata E</AU>
<TI>Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia</TI>
<SO>Journal of International Medical Research</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>3</NO>
<PG>230-43</PG>
<IDENTIFIERS MODIFIED="2011-10-03 14:49:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-03 14:49:33 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 12166339."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1991" MODIFIED="2008-10-27 11:51:06 +0000" MODIFIED_BY="Jessica Thomas" NAME="Nelson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Nelson OS, Munro AJ, Tannock IF</AU>
<TI>Bone metastatic: pathophysiology and management policy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>509-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Connell--2013" MODIFIED="2015-05-08 12:37:31 +0100" MODIFIED_BY="[Empty name]" NAME="O'Connell  2013" TYPE="COCHRANE_REVIEW">
<AU>O'Connell NE, Wand BM, McAuley J, Marston L, Moseley GL</AU>
<TI>Interventions for treating pain and disability in adults with complex regional pain syndrome- an overview of systematic reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<VL>Issue 4. Art. No.: CD009416</VL>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-05-08 12:37:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-08 12:37:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009416.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2007" MODIFIED="2015-05-08 12:36:25 +0100" MODIFIED_BY="[Empty name]" NAME="Palmer 2007" TYPE="COCHRANE_REVIEW">
<AU>Palmer SC, McGregor DO, Strippoli GFM</AU>
<TI>Interventions for preventing bone disease in kidney transplant recipients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<VL>Issue 3. Art. No.: CD005015</VL>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-05-08 12:36:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-08 12:36:25 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005015.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parfitt-1999" MODIFIED="2012-01-09 08:58:54 +0000" MODIFIED_BY="[Empty name]" NAME="Parfitt 1999" TYPE="BOOK">
<AU>Parfitt K (Ed)</AU>
<SO>Martindale: The Complete Drug Reference</SO>
<YR>1999</YR>
<VL>32</VL>
<PB>Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paterson-2000" MODIFIED="2012-01-09 09:01:43 +0000" MODIFIED_BY="[Empty name]" NAME="Paterson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Paterson AHG</AU>
<TI>The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases</TI>
<SO>Cancer</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>Suppl 12</NO>
<PG>3038-46</PG>
<IDENTIFIERS MODIFIED="2011-10-25 22:32:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-25 22:32:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="    10898349"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Portenoy-1989" MODIFIED="2012-01-09 09:02:00 +0000" MODIFIED_BY="[Empty name]" NAME="Portenoy 1989" TYPE="JOURNAL_ARTICLE">
<AU>Portenoy RK</AU>
<TI>Cancer pain. Epidemiology and pain syndromes</TI>
<SO>Cancer</SO>
<YR>1989</YR>
<VL>6</VL>
<PG>2298-307</PG>
<IDENTIFIERS MODIFIED="2011-10-03 15:02:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-03 15:02:14 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="    2655867"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-04-10 22:55:36 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre; The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-1995" MODIFIED="2012-01-09 09:02:11 +0000" MODIFIED_BY="Jessica Thomas" NAME="Robinson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Robinson RG, Preston DF, Schiefelbein M, Baxter KG</AU>
<TI>Strontium 89 therapy for the palliation of pain due to osseous metastases</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<PG>420-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roqu_x00e9_-2011" MODIFIED="2011-12-12 13:37:44 +0000" MODIFIED_BY="[Empty name]" NAME="Roqué 2011" TYPE="COCHRANE_REVIEW">
<AU>Roqué M, Martinez MJ, Alonso P, Català E, Garcia JL, Ferrandiz M</AU>
<TI>Radioisotopes for metastatic bone pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2011-12-12 13:37:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-12 13:37:44 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003347.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sze-2002" MODIFIED="2015-05-01 15:50:18 +0100" MODIFIED_BY="[Empty name]" NAME="Sze 2002" TYPE="COCHRANE_REVIEW">
<AU>Sze WM, Shelley M, Held I, Mason M</AU>
<TI>Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1. Art. No.: CD004721</NO>
<IDENTIFIERS MODIFIED="2015-05-01 15:50:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-01 15:50:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004721"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wong-2002" MODIFIED="2011-11-21 13:45:52 +0000" MODIFIED_BY="Jessica Thomas" NAME="Wong 2002" TYPE="COCHRANE_REVIEW">
<AU>Wong R, Wiffen PJ</AU>
<TI>Bisphosphonates for the relief of pain secondary to bone metastases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-27 11:57:11 +0000" MODIFIED_BY="Jessica Thomas">
<IDENTIFIER MODIFIED="2008-10-27 11:57:11 +0000" MODIFIED_BY="Jessica Thomas" TYPE="DOI" VALUE="10.1002/14651858.CD002068"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wong-2012" MODIFIED="2015-06-28 14:17:32 +0100" MODIFIED_BY="Denise M Mitchell" NAME="Wong 2012" TYPE="COCHRANE_REVIEW">
<AU>Wong MHF, Stockler MR, Pavlakis N</AU>
<TI>Bisphosphonates and other bone agents for breast cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-06-28 14:11:29 +0100" MODIFIED_BY="Denise M Mitchell">
<IDENTIFIER MODIFIED="2015-06-28 14:11:29 +0100" MODIFIED_BY="Denise M Mitchell" TYPE="DOI" VALUE="10.1002/14651858.CD003474.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yuen-2006" MODIFIED="2015-07-02 15:14:11 +0100" MODIFIED_BY="[Empty name]" NAME="Yuen 2006" TYPE="COCHRANE_REVIEW">
<AU>Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD</AU>
<TI>Bisphosphonates for advanced prostate cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4. Art. No.: CD006250</NO>
<IDENTIFIERS MODIFIED="2015-05-01 15:55:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-01 15:55:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006250"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zojer-1999" MODIFIED="2011-10-25 22:33:13 +0100" MODIFIED_BY="[Empty name]" NAME="Zojer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Zojer N, Keck AV, Pecherstorfer M</AU>
<TI>Comparative tolerability of drug therapies for hypercalcaemia of malignancy</TI>
<SO>Drug Safety</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>5</NO>
<PG>389-406</PG>
<IDENTIFIERS MODIFIED="2011-10-03 14:57:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-03 14:57:39 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20019481"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-07-01 15:25:32 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Martinez_x002d_Zapata-2003" MODIFIED="2015-05-01 15:59:49 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez-Zapata 2003" TYPE="COCHRANE_REVIEW">
<AU>Martinez MJ, Roqué i Figuls M, Alonso Coello P, Català E, Garcia JL, Ferrandiz M</AU>
<TI>Calcitonin for metastatic bone pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-05-01 15:59:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-01 15:59:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003223.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed_nez_x002d_Zapata-2006" MODIFIED="2015-05-01 16:00:06 +0100" MODIFIED_BY="[Empty name]" NAME="Martínez-Zapata 2006" TYPE="COCHRANE_REVIEW">
<AU>Martinez-Zapata MJ, Roqué M, Alonso-Coello P, Català E</AU>
<TI>Calcitonin for metastatic bone pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-05-01 16:00:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-01 16:00:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003223.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-07-02 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-01-10 11:08:52 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-01-09 08:51:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blomqvist-1988">
<CHAR_METHODS MODIFIED="2012-01-09 08:51:02 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 13:54:56 +0000" MODIFIED_BY="[Empty name]">
<P>N = 50<BR/>Women with breast cancer and metastatic bone pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-09 08:51:21 +0000" MODIFIED_BY="[Empty name]">
<P>100 IU sc/24 hours every 21 out of 31 days, for 3 months</P>
<P>Follow-up: 1 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-09 08:51:37 +0000" MODIFIED_BY="[Empty name]">
<P>Pain assessment: use of analgesic drugs, VAS (20 points) and 5-point pain score</P>
<P>General performance: 5-point pain scale</P>
<P>Biochemical parameters</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-09 08:51:51 +0000" MODIFIED_BY="[Empty name]">
<P>2 participants (1 in each group) lost to follow-up due to progression of illness<BR/>Adverse effects: 1 facial flush in the calcitonin group</P>
<P>Funding: Sandoz Ltd</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-10 11:08:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roth-1986">
<CHAR_METHODS MODIFIED="2012-01-09 08:52:25 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 40<BR/>Women with breast cancer and metastatic bone pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-09 08:52:35 +0000" MODIFIED_BY="[Empty name]">
<P>100 IU sc/24 hours for 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-12 13:42:41 +0000" MODIFIED_BY="[Empty name]">
<P>Daily analgesic consumption by the participant</P>
<P>Lasting pain</P>
<P>Participant's own assessment of pain (VAS)</P>
<P>Assessment of the efficacy of treatment by the investigator</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-09 08:52:48 +0000" MODIFIED_BY="[Empty name]">
<P>2 participants lost to follow-up<BR/>Adverse effects: 3 calcitonin participants and 1 placebo participant felt pain at the site of subcutaneous administration</P>
<P>Founding: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IU: international units<BR/>sc: subcutaneous<BR/>VAS: visual analogue scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-07-02 15:13:28 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-09 08:53:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allan-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-09 08:53:58 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome assessment before 1 month</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-02 15:13:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beaufort-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-02 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment of pain was performed less than 4 weeks after the treatment</P>
<P>There was no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-09 08:54:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berrenssen-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-09 08:54:07 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome assessment before 1 month</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-06 01:48:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El-Wasseef--2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-06 01:48:16 +0000" MODIFIED_BY="[Empty name]">
<P>There was no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-25 22:35:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gennari-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-25 22:35:06 +0100" MODIFIED_BY="[Empty name]">
<P>There was no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-09 08:54:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hindley-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-09 08:54:09 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome assessment before 1 month</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-09 08:54:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kleibel-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-09 08:54:10 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome assessment before 1 month</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lepidini-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open study with no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-09 08:54:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serdenge_x00e7_ti-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-09 08:54:14 +0000" MODIFIED_BY="[Empty name]">
<P>The study design was single-blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-09 08:54:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsavaris-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-09 08:54:30 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised study. Open study with no control group. The doses of salmon calcitonin were 300 IU intravenously daily for 5 consecutive days and repeated every 2 weeks until no response was noticeable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>IU: international units</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-01-09 08:53:07 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-01-09 08:52:56 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-09 08:52:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blomqvist-1988">
<DESCRIPTION>
<P>The authors do not specify how the random sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-09 08:52:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1986">
<DESCRIPTION>
<P>Not specified how the random sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-01-09 08:53:00 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-09 08:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blomqvist-1988">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-09 08:53:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1986">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-09-13 14:17:49 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-09-13 14:17:49 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2012-01-09 08:52:16 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of participants</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-09 08:52:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blomqvist-1988">
<DESCRIPTION>
<P>The placebo was a saline solution, but it is not specified if it was identical in appearance to calcitonin. Therefore, there is doubt around the blinding of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-12 13:40:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1986">
<DESCRIPTION>
<P>The placebo is a physiological solution in identical ampoules to calcitonin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2012-01-09 08:52:19 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of investigators that implemented the intervention</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-09 08:52:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blomqvist-1988">
<DESCRIPTION>
<P>The placebo was a saline solution, but it is not specified if it was identical in appearance to calcitonin. Therefore, there is doubt around the blinding of investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-12 13:40:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1986">
<DESCRIPTION>
<P>The placebo is a physiological solution in identical ampoules to calcitonin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2012-01-09 08:53:07 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Incomplete outcome data</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-09 08:52:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blomqvist-1988">
<DESCRIPTION>
<P>There are 2 participants lost from the data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-09 08:53:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1986">
<DESCRIPTION>
<P>There were only 2 losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2011-12-12 13:44:05 +0000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Selective reporting</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-12 13:44:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blomqvist-1988">
<DESCRIPTION>
<P>The results of all outcomes specified in the methods are presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-12 13:40:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1986">
<DESCRIPTION>
<P>The results of all outcomes specified in the methods are presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2011-09-13 14:20:46 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-07-02 15:13:39 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-07-02 15:13:39 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-01-06 12:47:42 +0000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="6" ROWS="10">
<TR>
<TD COLSPAN="6">
<P>
<B>Calcitonin compared with placebo for metastatic bone pain</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: Patients with</B> <B>metastatic bone pain</B>
</P>
<P>
<B>Settings: Hospital</B>
</P>
<P>
<B>Intervention: Calcitonin</B>
</P>
<P>
<B>Comparison: Placebo</B>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Placebo</P>
</TH>
<TH VALIGN="TOP">
<P>Calcitonin</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Complete pain relief </B>
</P>
<P>Follow-up: mean 1 month</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>250 per 1000</B>
<BR/>(55 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2.5 </B>
<BR/>(0.55 to 11.41)</P>
</TD>
<TD VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Less or equal analgesia consumption</B>
</P>
<P>Follow-up: mean 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>917 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>962 per 1000</B>
<BR/>(825 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.05 </B>
<BR/>(0.9 to 1.21)</P>
</TD>
<TD VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,4</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse effects</B>
</P>
<P>Follow-up: mean 1-12 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>45 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>159 per 1000</B>
<BR/>(35 to 722)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 3.5 </B>
<BR/>(0.77 to 15.88)</P>
</TD>
<TD VALIGN="TOP">
<P>88<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The randomisation was unclear<BR/>
<SUP>2</SUP> The confidence interval overlaps no effect, small sample size.<BR/>
<SUP>3</SUP> Wide confidence interval<BR/>
<SUP>4</SUP> The blinding was unclear</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-10-27 11:37:06 +0000" MODIFIED_BY="Jessica Thomas"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-07-02 15:49:34 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-07-02 15:48:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Calcitonin vs placebo (ITT: worst-case scenario analysis)</NAME>
<DICH_OUTCOME CHI2="0.33671288894009477" CI_END="15.877579370205757" CI_START="0.7715281853975237" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.200784292405049" LOG_CI_START="-0.11264820370449742" LOG_EFFECT_SIZE="0.5440680443502757" METHOD="MH" MODIFIED="2015-07-02 15:48:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5617329451784274" P_Q="1.0" P_Z="0.10442567551216636" Q="0.0" RANDOM="NO" SCALE="325.1453105905264" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.623766391077235">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Calcitonin</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcitonin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.61400983214693" CI_START="0.1940427909257189" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3141624788530009" LOG_CI_START="-0.7121024875250384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="29759" O_E="0.0" SE="1.1902380714238083" STUDY_ID="STD-Blomqvist-1988" TOTAL_1="24" TOTAL_2="24" VAR="1.4166666666666665" WEIGHT="50.0"/>
<DICH_DATA CI_END="39.05869370178205" CI_START="0.6400623684672634" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5917177144358472" LOG_CI_START="-0.19377770576380962" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="29760" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Roth-1986" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="50.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-07-02 15:49:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Calcitonin vs placebo (per protocol analysis)</NAME>
<DICH_OUTCOME CHI2="0.0029145260584916405" CI_END="19.23679504354019" CI_START="0.5383794021527437" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2181818181818187" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.2841327178656459" LOG_CI_START="-0.2689115641305204" LOG_EFFECT_SIZE="0.5076105768675628" METHOD="MH" MODIFIED="2015-07-02 15:49:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9569460633390804" P_Q="1.0" P_Z="0.20011515895665197" Q="0.0" RANDOM="NO" SCALE="333.0836054947258" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="1.2812235431603485">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Calcitonin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcitonin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.02229214079287" CI_START="0.12853049685811227" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8452363230500497" LOG_CI_START="-0.8909938136107249" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="29763" O_E="0.0" SE="1.6072751268321592" STUDY_ID="STD-Blomqvist-1988" TOTAL_1="23" TOTAL_2="23" VAR="2.5833333333333335" WEIGHT="34.54545454545455"/>
<DICH_DATA CI_END="29.24514359023871" CI_START="0.3799301267517019" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4660537580397492" LOG_CI_START="-0.4202962674790739" LOG_EFFECT_SIZE="0.5228787452803376" ORDER="29764" O_E="0.0" SE="1.1080513425729774" STUDY_ID="STD-Roth-1986" TOTAL_1="18" TOTAL_2="20" VAR="1.2277777777777776" WEIGHT="65.45454545454545"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-07-02 15:49:34 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Calcitonin vs placebo (ITT: same as control scenario)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.996736507132542" CI_START="0.5000906690184124" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="1.2551937581342485" LOG_CI_START="-0.3009512486949237" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2015-07-02 15:49:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2294146802627829" Q="0.0" RANDOM="NO" SCALE="564.8720620492264" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="1.2018680410954223">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Calcitonin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Calcitonin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.16470334946774" CI_START="0.1282696223366598" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8461186933890088" LOG_CI_START="-0.891876183949684" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="29767" O_E="0.0" SE="1.6083117442419756" STUDY_ID="STD-Blomqvist-1988" TOTAL_1="24" TOTAL_2="24" VAR="2.5866666666666664" WEIGHT="33.333333333333336"/>
<DICH_DATA CI_END="26.450125630660757" CI_START="0.34026303412212444" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4224277391527982" LOG_CI_START="-0.4681852297134733" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="29768" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Roth-1986" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="66.66666666666667"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-07-02 15:14:41 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-07-02 15:14:41 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoEAAALsCAYAAACcOW08AABgT0lEQVR42uzdD6QV+R8//i9ZSbKW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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-02-16 08:55:20 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADnCAMAAAD4paggAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAXg0lEQVR42u1da2wc13U+fMyLu+RyhmQsVq0gkkr7Q/3RCrAhyqYf
K8upWjQOCrgVHMd184OGYzdt4AK2U8CwUaCS0/iH4QRNGSOKnLiN4cCoHSBSLWmdmKTrUIGAAFVa
tEtSlS2uXHFnSIrk7Owsyd7HPPdBLsldcrk8nx67c+65j5n95t67d+83BwCBqBoaQMWLgKgSjEa8
BojqAemFQHohkF4IBNILgfRCIL0QCKQXYtvQjJegsjDwEgRW6pFeeMNWGjkcHBE490IgvRAIpBcC
6YVAeu0Y6FueEVElesUJxJZU0aTtOre9JepWo2u0sETGeHHvFQ1pVPXeK5FI3BD6aurc+kmrivVN
5v9uLKN7pnnHORN7u60YHLXJHECXIkrkdo63yyJ5GWuR6BKuHREjNjVK4mlTFoaZuylI8jBNE6I2
9ZTVOO8ayD+9RYroLINkkjSZFunYgJXaTpzsKC81dlw0vXLiMdlpQ5z9oXbu5db7ltkBpigprG6R
5gGvLFs+6mdskVr8NrB6FVYSQKciyuS8hkVR7gRhsQ95tBVzr14B4FYkG1kg75enouQlLqeWyEHH
O1mxgxpTF7/SPTV3lHm3Ra3z95O0pE3T4v82FegE9s1a51SWYSYGcJ9y1fRtALeLqWVaqpGVaKnw
xsU2rxxomoL5SHZmgfQyrJ/peIfbwa33ayOs7vdo3TO8Xaws+q5d+dWim1GVLHmf1wZW7/Uk917Q
sy2LAEej2fPzACNZ5FG16UXnXrkZgMw06HeS46safckltTQ5sA7BeIa8prWB/glNuYvlkOzhgxZJ
6wadvNgHtcCPCTkBBhRWCnXOjXebvg1AmeClCiwnTGoDA145kNTAnAblTreoE07dk269SwdJ3Vle
t1MCe2dYtKbpjNeGcUjmvDZQGFo39zYVdpKC1XmQuB/MIY9KoFJKoXgCTG2O9F7p3txyf4Ie039i
lr3QI/LWMbJ/hFDtXzzTdpMNh+T+F2zPk75wo3uUcKfUvKMYHPKcxHNFsqR7l5Z4G5zMkhWol7aJ
1t06HcgTyA2BjIFGQ6AkvWcpdyQB6X12w9Vu3h4XBv7mmPMoVUmlkCI9Tf5/BKbnAuzVgc5tRvUi
X/aFhVMtt8iHSr4UkA/8bu7pLAuMcqODUZbZt73OfWnOc57TiJ/lEbjpfzkcIXWvBOsd0Hnd88Ei
ndwNgWbSRg+EWmyD/ufOV0vxAzqiLtxQHiENPoPd1BbMvWZeI7Pli+fNDt+U6YNOOg4egD45310e
1t4lEzO5C9QIwCWFeY6aOuU+6ctOK55n84GUwmwmL8TshQ4ygZJtuNDiF8fLobg4bVoeK+X8uj+6
Qowmq1tKuXlIWSop66O+LpkxkrZBgQO/CLU4BsqP2Jvl/0rez8/gJ+SUr2CHtSVT+9ljOsze3R0o
81JWbqBzLkvMpvO9W4+JbCQzxQwhz9VOiXrOxPZ8n375j4lP+J3gzGIP+cAT7aJ6i/e5lkTrSLcL
L0c8J6cc1o5W1obmPVCsbpHMpFo1Xvdn3TykrMOkrPfNOUIy8Ta2ANEhmuFFiFm5i5fU8mVWQfSY
dHQW4C4ReVTluVelJnBlL4KY5kZr0b/4w45Kttr+/Bsazr2Kz72aQKmddk0tlef3N79sWvr5dzda
y0vphQ8r2epY6sXAUQZ/xV32KJXBZ0xUGLgZOrAZGrvyql1aBOCGHATSC4H0QiCQXoitBE7t8Ztj
Fb/eIL3whq00UEaLwLkXAumFQCC9EEgvBNKr2tC3v2gUlu1cemlxulMrXlJeu3dzwtvV8j7PX8xX
1sjz/LpktFETaVQ79MqOda6avrqGdVP4Ne+b1P61/dYho72mYm9XM/TSbSPnfRw6V6raCtXBphRR
vuBqWPUWUdE9NS4wea7p63Fjijjs5nNsXYokcde4Kg2apiyYAaUt9Y/zjueydAdokqiYTI/bwhuj
R0T6LqVIpq+/FR1drsj1t9DVwtrk1WWKgjIMmogy2lLY8t2qL0SX5L8VoGeS/v22NN/6zSzExJlY
Dn59ubH19dxkT4KmnGpdaCMpPdc//s4C28PayHxUYSGiWNCTunY8vuzkUw1o/eqHsBy9Nd+4xAq+
/slXmtuv/eGbS/DMeYiSNO5PiyZ4+6enYblloe1YEv7l/e/MvdzA6luExO80wDejLQ1LThNIXS2s
ro9pXQQ9H18bep55O3VFWhZvvZWDC2ds//xwt2pwt+qWX4whEURPFmgnIUk+muyEkAE4q4BxxE2R
x1mKo8YleJj5WOMw4StneT6qhX2V6XdduWtam+6f0AbI0asCGK96/hwPHwRo1s3kWVL/HaBwFZHC
NbqPT9y0XL9wXcDe3eTeTl3/kDNNKqO1sZsqga3eDK0/tAIwmtIKlKokaf9jQ0cSq2lYIc8cktfa
nbm7rURAiltKjktltPpvLq3EbubJaIfttWW03ODUNXZvDhJ3MW2tB9z/WyUZbVlQ/j2RSDRdcY6o
UrXBFSTubfzhLc/PSYGgAbgmtsDGFbAxmH63oLqRkBzXX3fQFlPRuaCMlr6zXYWjk7dA+9vptsmp
647FG5GjuI5RQ1N7qlIF+bJz9I0rcEAAEHptYl4WkvTOHx6jKVTDKgQzch/5APTK+Taups2F9Lvu
GGt72lpKGDaKiWQQPK6xbwHCGGjOcMd1u2KfLbl+Xw3VxVY04Lf5EyicuhRNmyKdsYIdVq3QK5ck
/yWfcW74L31OylwD+B8reh4gMv8s/cwlNoG61sFSfHCfSWvQTufZ0u3CHxMKzb7e/XZBden2wYwv
5BbYowH+9TaAS6awMENquU962FHmxiSq2zXMJ2dcv5OWYIe1v0nF5Nu5nLreM8V24nrbO8ijGpl7
1QD07uE7KlmeHU2hjLbE3Gs36hw1a6GSxb3yYnDyhfTa7fSqKnAzNMpot+LSIgA35CCQXgikFwKB
9EJsJXBqj98cq/j1BulVd+PBtjcAZbQInHshkF4IBNILgfRCIL12C/QK+SC96gM0JhsN0lig0I2v
Kq41xZWi9qCct1T2vUig1VFP614J0C8/4LwrSCqJWLR4OMb+hJ+rVPb+BDJoFw2O2v1LXn8VOy7y
eLOaY1CZIldX5HbeGY21iMoYxO/6PZbDdLS4PJauKrtaWkU8zbNrTHE7rAg0Di2PbUs9TEFSOpFH
u2Pupfob6+GNiz8A6Dh7w11E5vFx35Smlvnx7XJWvt0NPQtDN2g02j9zYunClBuS9iexJ7h7OiW/
CfCAbtM4tDy2LfX5q6j13p8gj3YBvcjk6/f9edSkNpAEsH5Xu+oZqCL3xzySLYGchHFfCdSv0Zi1
33Ji6Y67u+ezh2464WlzWvLHXhxaP7btP9vDB4eQRyVQR5uhqco11ZMJiGDJP6pwDRmc+LiOv2CH
I83aXXYglq6v1PVEtXrPjHIk6GCrVmPrtN8KA39z3EYZbZXRvVy4djAWvvieOJYqdRsDftQcW5mO
htxHvbUHm2lo9zZ0fBByEOY/pXFtEbth7nVByDNIl+H+8DpEL+znD7wRrkCfF5cd9kOfRG48HsfW
J5ZwucsZQDvhAPFe/s9koLwR3Y1ri9gFcy/x8y15tvQXpKaQ4VJWauQnbXxOsvzdWU0sZu1s60Pu
FeGxbJWX5xyfBtG6BBD5cjDYrrAHWlUxjssTu2DuVf7yRWax6MRtzZldOcC5V81Go90KtK00L801
FZivrzXAXS9zBMw0bH+Psc0IPN9r1+1WpQHghUJzdq182bIv7rZ/ujV0tXEzdIWBMto6/uaIQHoh
kF4IBNILUdPAqX2FgTJalNHW9XiAMloE3msIBNILgfRCIL0QiB1JL71MW1G7vmVVl1kfimfLRnC/
VxxguDky7W8x9xISq2130hboJpRV90O1LBamtyyW6StnnDYUooxNWHKmMIOcKczpG8I5ikAxV6kY
93uV3GufSHwq833j69GhLsw0wBoRZA8XST9c2jeMI2s1YFUcKdOWWDU1hCrGy63zwVEzHnU7sni7
PMhivQ66OtR2STJpnFj5Ateh8liy8Tv/yM1xgcZtVWxIK6C/IkbIIGJKNF6rF2FWogrWTmVQUpkl
HREjaZYPhgdFuZOXQ1w0Fuy16yn64sSQZeWTBpgsNmx8WGzhejKvDC+NtDiiu+2nuUm91JCODKrg
VfGBRH31pwcjNoTaz3JEmGaWFKGkwVYCx06D4l4kXW5DlNeTXnjLe7sy9aUYwHPiKTdu03Jqhhj2
i1Pn+PE+2ZL2QUArf25q9igI34N3BVD7s9Pkw4wptn7MdVGlFN3qdrs+FFlkth4xK5wklo+n4Gh/
9vw870WIby5Fxay3fmRF5kPlpy5o3bQOgOM3pB5mOzmTlU6G0jpmhqT9bvtpbvVnFm1Lj3hqCbwq
3k1RX/XU0LQfR421n+WYsb5Ni2iYWnwXPiN4x8tTpF3e2VhUr81tiDLoFY/H/z6kQ6XxXMc192e0
q0w6mp3QTvJjOwnjoUCsX6cOYgaekkC+AxQFoJnHa3XmLONMwXrWUaLyeK80VuyDGoh/2XnQn/Pw
GLSZadDvCpc/0D/B9asGU70CizdLY9EG0k4Qywmv/XQyxdtyYtxT1LpthccFUE7k2YDFpv0Luj11
XBt5Cl4QvWMvNi47G0jKeTZEHprz5h+d/mfMu/wVDbR40LCkuZuJ7yRJYmhopf/992/A0k2gV3wE
4Gf3xvbY7t7jZZ5z7NhSLlwAyWe0z3Z3ToerZjFf88t3BiKBDKC8DF5RIC1JmnvG9/Rczgx5Z1Lg
G7Q5069hZjiYg3PTgePABI40XsizIdYYHKcfzTM8lh+TtVEHp8sqiBjLP6Om9pe8OK80Xms0kJMW
dU/DT52oswf8soWFT5V8NWpspUh8WW9xwMl5oCDeLK3ayjdkg3lW8fXN/CS1b7QPB48DPiEVLqIs
erW/kWdo64X9IYPUC8+NcEq8A31FVBHioTYysI2BxqO+0nitPIaw2ccUrEuCTKc7xNamePFe5WEt
xWdGfrzh3AUW83WkWCR0rnql7bNBPR5KytjBJ5mM2izmrMIavt+zuScT8uUg9TmxaVn5h0QIHkMw
Xm4GCbSuuZdgz+Q5nLQHw7Ktq5b0Gu+zrj0pWtcKi/y/0QfJYHevuDgH8D1TjJHeS2SSVMOS3m6k
UWcHaInibXCyy4v3Gj0mts1xdt7mFjR7D4v5KkSLtLtJdHKebBcyvwwvu7SLmXF/9I/CtftYW9K2
5EwF/BLTIV8v9RKPTUvxyEgSgsfgxcvVpMwlJFD5y6plQzPNDVZ3+snFijS7doXRuKy6ORntyuP/
UUyHWgbaVprPzjZV5Ayu1+xjHVBGG5TRYjTaSvdeeAkwGu0WXFoE4IYcBNILgfRCIJBeiK0ETu3x
m2MVv94gvXA8qDSW8WIg8F5DIL0QCKQXAumFQHrtaOgbSqpglt2FHb1jouxdX76jUnqnWsviuksr
org1cDxYVnftxegvnXR4/aUdAURdD47xdhZj1paPaiy+bMsYjSUrSdppZqcxZHlEtLEITQuoasH3
B3C0sfZxGnvWjrDItPH2o5JmHhWZlliM8v355B29NzsflxwpsBO/FlGfcy8eY7Zd+dUijy9LuaKn
Ipm/ZnYaQ5aLz25/P5vmsWf3zVrnePft+jMw+ezTNPZsh5B9h/6asfxW62L3WxfbiCWZFbnatkO8
Qak5/4g1wwW185HsDMpo65ZeXMWaG5/OsPiySdrJGJp+mMeepTFkebfjaGmpSYAB/s7198Bjz1oT
cIgLZKePTGgDA8TSDTrXq1njGtVvZAbAUdya06CgjLZep/Z+WFhnzj045NoCMWTpO5I+bLvvRrKF
/qFiJCtUjJfFiW5rd734LI9am+7N0fi1OLWv56l9g+78r58JJ9iu0rfBU8KOesJb399ZYeAaS/K/
vhIqZcTX6nItbtuyI5uD34LpKPZSdTs4cnzUR4PG/uIKHMjT9Xa6WtcLNtPSjuo0frajiXX8R02d
3m/DOoiXbVKMdQAuh6XbcspV20q9rLtfSj/oKHwD8WsR9Uqv98058vFfe0DK5Ol6G1kMWdpPxyRz
jsWPTcTEJ37ObI7/TGzP9ylz9oDycvQ8mZxZwhdyoVLSn3XVtmlbory62OoqfGdbu3E4rM+5V1mz
sy0Gzr120bLqCHYg24o6362a3YZ7F0m1a+i19UAZbR1O7RFILwTSC4FAeiFwar8bgTJalNHieFBN
oIwWgfcaAumFQCC9EEgvBNKr3qBvQQ6kV/3CjgxKbT4l4nnJewtNa2D9OZBe9YuYcCq1ykaG9ceW
xWi0SK9A7zWhaXMyeY2KEVcLK9B3tuxIYeMg2zAmu3Zg6lzXnypxdZqbpcVjshONNh5TnNi3KvZl
u5he0n6tEyyADiMrPscsHUm2Y16VWw87sWWf+gw8ILl2ioYpzz+XkvaRPM22SH/iaJrywuNen41T
+ymci+1mehlgzj3VBWAJYLzKLCe6Wbxae2L6rOPzdzZV1zp2inHN809rNObuiQkYf5wcJT3F/6Sm
DBD7pIY/M5bE7ogppPdmMq4W1lHFjlq+aDae0LstOePawZHPev6OEjegrfUFvI6u1iczfhffXU/I
EXXQZlaCWlgnBu2oP6ppQkzMj03r+tss6uyoXmJBQseFitJYf8C9HYevPZp65p9WbIjMN6lNNvRM
QqRtUW20QflW9J4kfPLRd6np0KcZ105ALJ7/n344dKsBcq+Z9IUmXL/5Enmh72jGV6x/nAiE/9v+
gHvbjhU/4N4u6L2+vrKn2/6ERp4dzHCp9eQiU8UaD916240tO35g3LM7cP3/QHrBoNpaMet0U+Kz
gdInc1LjY9hN7eq512awthJXzS7g3GvXzr02idE1RgJJtGbwKpUA7lZdC2s8oKTBgmzosSkoo0V6
VQ841wgCB0cE0guB9EIgkF4IpBcC6YVAIL0QSC8E0guxJoxtzl9bBSC9ENh7IZBeCEQecL9Xjc29
6gH+fi/cMVG1a7tBem72dq+BAnBwRODcC4H0QiBwao/Yju85OLWvxndHlb2o5U+TvTzsdV1Z/em0
urG6/em4WnYLeJLf6lKVIr0qzi5+kdnfstnlfjCqc1R+1tAX1o3U7Wc3oNwWGHlnWrJSnHvV0GLG
xpcEDLVi90VFa8Peq8od2UbG1Q1kNfIX3NZft1p2C9SyTxjpVa0OyaB/jbK/ObljI3ldb1bwcm6w
7oJyNtSCYnmQXtUc8JyZyTrHyA1kVTdd92ZbUDwPzr1qY2w0Njm0bX5cVjc/myvMg/SqISZu/Ofw
Sv2QXukf5HFZtfJUCa4SlHd5A6tO680arnQTBajraXyxda8ieQykF6KKdxoOjogqAumFQHohkF4I
BNILgfRC1AUCPwqhxgVRIahF6IUrYIjKwMDBEYFzLwTSC4FAeiGQXoj6QvPqM/+d950S217z9Mrv
05Z38BnldlLb82JBruDgiEAgvRA1Ti+jzNQCP8Pwrdv0w5NRtHJjR5yP1/ZSTarlS18pIdpajyPY
aXPVGjwfdQde+vUPjobh3EnenWGwP05K8I7jnkbeneS4+d5b2o25lQfPxn0xavp8eF0Qan+tX/p1
917FnkRgqOGU4LH7VAtPYBl+8MWW80v1/xY2xm9rbZ4PrSdUea1f+g0Ojqrh/Mnrd9WCPrmgb1a3
tb9Wi9athl9r63yMvCtf2MDavfQVfAiAGnhI1dqXSzVqYia2yry3Vs6nDIVtzV765speB3r3rPFo
AiPwkLLt55caatOOPZ9abepG171U9hwVdSMrF4EvBVt29Y2CgcNYY9WiVs/H2Myi0ZZf+uZ1npha
umf1Uzjvwp6q4SXylC0dHPNqCzaGvnPaVPPnU7SdtXzpAw8B8O/ufO328k76WTj/N8ed1Pb83xzV
tRazavQ81BIfBqK2PzfYYbsokF47CTtug05xei3v4I8gt4PbvlJv90NzXdwk2PYaBW7IQSC9EEgv
BALphUB6IZBeCMTqCC5M4BOYENWjFz5/CYGDIwLphUAgvRBILwTSC4FAeiGQXggEArE2/h9RIeVu
MFHkcgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-02-16 08:55:17 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASIAAAGRCAIAAABOgik6AAAOoklEQVR42u3dv44kRRLH8ZGQEMYa
a/AEPMNaaIQFFu/EmmsggblvgXiEE9yZgIWHOGZPt2NgLODdHau6nhvpNOqprq6ZrsiuX+XnpzaG
3t2YIjO+GRFZ+efigogaaCCiMsGMCGZEMCMimBHBjAhmRAQzIpgREcyIYEYbcrKOVx3BjMo9TCPA
jGAGM0IazIgeWpipzYgIZkQwIzqaN8KMaHkPO/oNzIhgBjOCGcyI1GYwI4IZEcyIpqsyq0BgRgQz
2kpMm/4GZkSn+ZakEWbUPppJGokIZrSJ7BFmRJJGmBHMYEaENJjRmQsztRkRwYwIZkQTeWO3dRrM
qNzDDv0AMyKYwYxgBjOi+7WZs0CICGaU7GEaQStQu7wRZkSCG8xINIMZkfAFMzqPh2kEmBHSYEZb
qcrsN4MZEcyIYEY0J28c7DcjKvKwQz/AjAhmMCOYwYzofm1mvxkRwYzCk8aJb2BGtEyuaBUIzKhd
NJM0EhHMaBPZI8yIJI0wI5jBjAhpMKMzF2ZqMyKCGRHMaDRT6rkkkzTCrKpB53xJMKPHj9+P+1OC
GRHBbK1hTfMSzMoZky4SzGDW0MkcIIcNmGkNmEU2K8ZgBjOCGcxoc7WZA+So0LG0MH/gBLVpkuYl
mKlGxHaYwWwrrWGg0RCFpAll/AFmhDSY0YZKMrUZLTZscyyCGZ05YxTNiCSNMMv0MNGMP8BMmkQw
gxnBjKZJ07wEM0U/wYwMOjAjkkLDjFbEWLekwYxgBjPaXJEmaaSq6l+b8AdOUJsmEZeAGcwaxfbB
TCMhrbQpHIfKJ2oLM0fuwAxmBDOY0bbCu9qMOBbBLCpNmvhGa8CMONbyId0KfZjFYBbnr7wLZkm1
2agp3QczahQTVt6DkkaYkaQRZoEuVVr0x901w7tglhoZslZUcDCYtfCqBWdB4jAzoQ+zFi617GRj
YjQjmIXlSHf7S8fBjGg/yA+2dVJRQHMjjEQXZi2SxrrFVhFTIDCDWRJme56aNZsPM5hVVSN176aD
XNbuO5ipcwhmdJg0HQczzdr1FPZE0qg2I6ldVWsYaDTE2jFrsPYfZjATzQQ0mNFkNaI11Gb8AMBC
GczosMuqzWAmO6rab5blxBwMZsEBLXGlldqM+o2TBLNgKqRMBLPavM57M4MOzGCmNWDGsbQGzGj+
jIVBB2YwCwbY7mmYUVVkIJhR1R5nPQUzalGNBHWWV+owi8SMy8KMWkQzghkN90syzSv8wozLNort
ieUlzDJcaln32sa2TpjRkuni9Jf9uKz7cWCWlNqFRjPT+jADMMGMCGZEj8gbYUbrnUVwuDfMiGAG
s/w0yTmNMKNCr4qeFlebwSxp8E7sKd4FM76lKWC2lcKsaCFISsdxMJhlR4bQxVYwI5gRzALzxgjL
BDMxJ7UdJI0wgxnBDGaHk0b0wkyz1s7mO88HZlQeJ2EGM4KZShVmxS5VvQokZcrOKSAwo7NFM0kj
SZMIZhGtWZAm2W8GMxK7jrdGz+/6YEZNMRvMNNL606S4VSAwg1lYmhTqskVXBMMMZiUwiAwwI5gR
zDaRJiXOjJvQhxk1GnFEMw3BsbQGzPhWfTqKNJgFtmnlGfoRUyBW6MMsO0iaaTxEMsyoR8zq9isE
rZaEWe0ou3j33+2vzrd1Bg06MBNzUuc/YAazhbt/2kK3PZgy7wqzmFF2tKd0X1IRoSFKy5IIyxtI
RyWNRFVjjQl9oqoKKshvYdZouMWY3dMwq60ZtEYRZpJGjtV10d8AM6tAkHZR0k/J5zRWhLKUdBRm
LQqzxcdvghnFe23KfKBVINQoVEZMVOg1mBXCkOKvpRMVXm/ALMxl1TmDVSCUm4AF7WQbbQ21Gcy6
TsCqL7xfP2kwS3KsNmGhOtFdv2WYUVidUwpDynAGs1QqhrQ5zIgiCmbx8WHNVZ8UGmbBsyBDzYkg
Pa92hxlNpUlrxkzSCDOYlSdgFT7gcG+YnaEaWf/ppUFm99p58Hqa4saFCK+wEYba8dDtM8OMkvK6
ljHH7mnqGrPQnWxWgVDeREXPMQdmqRXUUHPxUujuaatAqCoyDLZ1piW6MINZi8cO3bwjmsGsO986
FHAWX0gNs95rs8WXRIW+N5sYg3ogDWZUPjSMflOxwrP0MIhTjMOMpmBYM2ZtKtVFIjDM2nVSxfia
e5TAmjFbfGiAWVJkyBoaztLUMINZTGGWtIKpyWyTpLGj6YQhaoX+/yOAbZ0wi4yT69/ISDDbCGYL
TiQ4p7E0a4BZo7JhtZjl1nstX0KIZgFTIEUBrfOVhzCDWfZjd37u/1C0fQkbnZPWxmWrK6jSdBdm
ATXJ4sarB+8+68lal8BGVswJOlcDZjCDWfzQsGz4LXq9AbPavHFwfE3ZdbuuERRzYlK73CVRQfeA
wkxqt4WsYcFBp+KVOsxgVp6ApVwoUZd8wixjlC0t+tssiWpwzpdVINSXY5Vi1mB3nFUgMOsdswbP
rDYLyxgb7OrN8tp+XQIbQfV03NDgmWGGtBYeFtfIy9ILszDMQs/VaPO0Xk93XZtFRMU2AJf6G8xo
7bMUd3+oenEUcsgXzJDW4rbOZSND6JXZarOwpHHh3ur+MJ9Ul9AQdTEn7qDsrOzOFe8YCyMttJ6s
+F2Sxq4xi75DMKWdTYH0WECnA9z43haYUS+ONVGYxQ0NkkaYBZx0n56MnE4yzGr7aVj3Wru68Ztg
1ijmZB1SUHGv+eB+M5jBjNrkIzALw0xql9iDMGuRg61/CkTMgRkVYrb+bSntswaYIa3q1OEiDBIP
8xkstopL7nOnGddseYiaaoJZ2Cgbl+C13PG92meGGcyonDSYwaw2MgyB866OQ02aqMhirM5lF7fc
4HBvSSOAC6cTIjCLS8Vh1m/BkI5Z3uDIgzvHLLE2G3JuToMZ0uKbwnszqi3MHOYzFK8CGazQ722i
gtpgZk2jvI7Kqz6YmagQJPPipN5KIq3xuof1rx5OGc5gllSbVZ/TODGcr8qyVSC0qZfIFdtGU15z
wUxt1mgZbp+Y7TU1zHokrSXAFeVZteUVBjeYtSjMtHBWCi2ade1SAG5WqarNqFEQjrAckajDbAsT
FWsuJqtLpogDyWGWkcxUvynKPa0xadjVECk1Q8vH7pY01wh2jVnLwizxGsHVZg0wS6rNBltsMsMv
zCIdK2UhRShmajOYjf9wos2K1K7Bu742Ac0K/YAKp89T48/V4KZAOs1nim6I1nFBOyFgFtBJoRE4
913fYFsnzHIjcKllUyC91wzrd9nQw73tnqakOOlw70MMD2YaYbbaa2DbWK5uZydbJSWNETBIzmGW
HXMoNIWGGcxSI3DKcXom9PslLXrVUlClWtJrwCgNCz3ffOmoc5ipRuJJazBE2m8Gs7W/6nUaF8zi
pxO0c0TM1FuFfW/zZXQKbRVIEmbrH2iHzG2d3pvBbGHM4q4aOktyvtoe1FXlpGleAyXMuFTqts6g
OAmz3mHYWLOs+jn58eIdX1GaU2irwqyq4+/Os5V23rJDQ9G76cUt12G2d9ehpHHtmJX6QcW0+OKH
ExZZriOt6Jlh1qKTKiLDyh2rAWZ17/pg1ilmdcVedDRr1oMwE81gBrPOMGsw7d5gBf3K35uVtvOe
KVMgqNZ3UeOvhiCCGRHMiAhmRDAjghnttRfRQ14nwOzBmLHM8kMtw4xjsQwzmLEMM5ixzDLMdD/L
MIMZyzCjh3bS27dvfvvtxfX15atXT3/55eLq6snr18/evHn+9u2vLC9o+c1/3ry4enH5w+XTvz69
+MvFk2+fPPvu2fO/P//132u0DLMlMfvjj5evXr2/86f7n52f/f77lywvYvnlP1++/7f3dwzc/+zY
+PIfq7MMs8Uw2w3Soy5197P7OyyfaHkXWEYxuPvZ/Z1VWYbZMpjtRu6jXnX7OTSKszzH8i7aHCXh
9nMo8rS3PBezQytKGvA5/SsO/enoJQajxyfO/HL6N+4qkLvZ0TffXHz00cV77918Pv304vvv9/Ol
P/+8ZvkRlndV06GMbjTHu/7X+S0/DLPR/zx7GBx9gOnTSEcffvrLo79xV+XfdZ0PPrh5gK+/vvjq
q5sfPvxwVrLE8lHLL65ezCRhIsFrbHlhzA7FuuljFfbOkBn954d+xcT5vo0xu76+HM2Ifvrp5vHe
fXf/+9evn7H8CMuXP1yOOP2txmB49t35LS+J2SGXPfTzob85gdlRKuY8cBFmt7PVe58ff7z4+OOb
/68vvtj/o6urJyw/wvLtDPt8GJ58e37LS9ZmD3LZOf9q5s03D8Xs/vMvUpuNDt6ffHJj5LPPxkt/
lh9heRyDu7rHw9ktt4hmC2I2kZfOnwJpGc3eeefmN/7884hXnRgZurW8/Wi2BswenTTOKSwrarND
n9PrnD4tq81OwmwiRkXUZntza7efW81/Lcuymcbj782O/unEv3rQX55z68p535tNO9Yp76A6t7zx
92ZnXF2xNlmrcV7LW14FArM5z2nlYRvL1jRuXzPWpD89vCb9c5YXsbyLPONzg//L6D5/tTrLMFs4
6h7aYTVagbD8aMuHdoWNVk1ntwyztSS3LG/YMsw4FsswgxnLMIMZyyzDTPezDDOYsQwzGm8vIjfC
iGYsi2YwYxlmxLFYhhnMWIYZzFhmGWa6n2WYRWPmdhWWYVaLmdtVWIZZLWZ2IrMMs1rMnKvB8hox
m79QZe//Yc7TuhHmqOXEU6KcbLVAWJh5x9LM4+4OWXYjzK0Szzzc+DmN7TGbuPzl/kUz940sgtn8
aOZ2FZbzMJt/RHHRqcMPTRrdrsJyXm12FLOj/2OPvhHmKMNuV2G56kaY6mj2oODjRphub1cRzU5N
Gkuj2SNS02HrN8KooHqszdokjYMbYcwHmmmcUzWdkjS6Ecbbra5vhEmRVSAsB98Ik47ZYE0jyzBr
gNngdhWWYdYAs8HtKizDrAFmLLMMM93PMsxgxjLMiGOxDDOYsQwzmLEMM5rTlERuhCFa6+isIYhg
RgQzIoIZEcyIYEZEMCMKwIyISvVfWq+SqbjNNEYAAAAASUVORK5CYII=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-07-03 13:52:54 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-03-11 12:57:56 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-03-11 12:57:26 +0000" MODIFIED_BY="[Empty name]">MEDLINE search strategy (2015 update)</TITLE>
<APPENDIX_BODY MODIFIED="2015-03-11 12:57:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>via OVID<BR/>
</B>
</P>
<P>1. exp Bone Neoplasms/sc</P>
<P>2. exp Neoplasm Metastasis/</P>
<P>3. exp "Bone and Bones"/</P>
<P>4. 2 and 3</P>
<P>5. (bone$ adj10 metasta$).mp.</P>
<P>6. 1 or 4 or 5</P>
<P>7. Pain, Intractable/ or Pain/</P>
<P>8. Palliative Care/</P>
<P>9. complicat$.ti,ab.</P>
<P>10. complications.hw.</P>
<P>11. Hypercalcemia/</P>
<P>12. hypercalc$.ti,ab.</P>
<P>13. exp Fractures, Bone/</P>
<P>14. fractur$.ti,ab.</P>
<P>15. Spinal Cord Compression/</P>
<P>16. spin$ compression.ti,ab.</P>
<P>17. Nerve Compression Syndromes/</P>
<P>18. radicular compres$.ti,ab.</P>
<P>19. or/7-18</P>
<P>20. Calcitonin/</P>
<P>21. calcitonin.ti,ab.</P>
<P>22. 20 or 21</P>
<P>23. 6 and 19 and 22</P>
<P>24. randomized controlled trial.pt.</P>
<P>25. controlled clinical trial.pt.</P>
<P>26. randomized.ab.</P>
<P>27. placebo.ab.</P>
<P>28. drug therapy.fs.</P>
<P>29. randomly.ab.</P>
<P>30. trial.ab.</P>
<P>31. or/24-30</P>
<P>32. exp animals/ not humans.sh.</P>
<P>33. 31 not 32</P>
<P>34. 23 and 33</P>
<P>35. (201109* or 201110* or 201111* or 201112* or 2012* or 2013* or 2014*).ed.</P>
<P>36. 34 and 35</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-07-03 13:52:54 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-03-11 12:57:06 +0000" MODIFIED_BY="[Empty name]">Other search strategies (2015 update)</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-03 13:52:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL (the<I> Cochrane Library</I>)</B>
</P>
<P>#1 MeSH descriptor: [Bone Neoplasms] explode all trees</P>
<P>#2 MeSH descriptor: [Neoplasm Metastasis] explode all trees</P>
<P>#3 MeSH descriptor: [Bone and Bones] explode all trees</P>
<P>#4 (#2 and #3)</P>
<P>#5 (osseous metasta*) or (bone* near metasta*):ti,ab,kw (Word variations have been searched)</P>
<P>#6 (#1 or #4 or #5)</P>
<P>#7 MeSH descriptor: [Palliative Care] this term only</P>
<P>#8 MeSH descriptor: [Pain] explode all trees</P>
<P>#9 complicat*:ti,ab,kw (Word variations have been searched)</P>
<P>#10 MeSH descriptor: [Hypercalcemia] this term only</P>
<P>#11 hypercalcemia or hypercalcaemia:ti,ab,kw (Word variations have been searched)</P>
<P>#12 MeSH descriptor: [Fractures, Bone] explode all trees</P>
<P>#13 fractur*:ti,ab,kw (Word variations have been searched)</P>
<P>#14 MeSH descriptor: [Spinal Cord Compression] this term only</P>
<P>#15 (spin* cord compress*):ti,ab,kw (Word variations have been searched)</P>
<P>#16 MeSH descriptor: [Nerve Compression Syndromes] explode all trees</P>
<P>#17 (nerve or radicular) near compress*:ti,ab,kw (Word variations have been searched)</P>
<P>#18 pain*:ti,ab,kw (Word variations have been searched)</P>
<P>#19 (#7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17)</P>
<P>#20 MeSH descriptor: [Calcitonin] this term only</P>
<P>#21 calcitonin:ti,ab,kw (Word variations have been searched)</P>
<P>#22 (#20 or #21)</P>
<P>#23 (#6 and #19 and #22) from 2011 to 2014</P>
<P>
<B>EMBASE (OVID)</B>
</P>
<P>1. Bone Metastasis/</P>
<P>2. osseous metasta$.mp.</P>
<P>3. (bone$ adj6 metasta$).ti,ab.</P>
<P>4. or/1-3</P>
<P>5. exp Palliative Therapy/</P>
<P>6. complication.sh.</P>
<P>7. complicat$.ti,ab.</P>
<P>8. Hypercalcemia/</P>
<P>9. (hypercalcemia or hypercalcaemia).mp.</P>
<P>10. exp Fracture/</P>
<P>11. fractur$.ti,ab.</P>
<P>12. Spinal Cord Compression/</P>
<P>13. spin$ cord compress$.ti,ab.</P>
<P>14. "Nerve Root Compression"/</P>
<P>15. radicular compress$.mp. or nerve compress$.ti,ab. or nerve-root-compress$.mp.</P>
<P>16. exp Pain/</P>
<P>17. pain$.ti,ab.</P>
<P>18. or/5-17</P>
<P>19. Calcitonin/</P>
<P>20. calcitonin.mp.</P>
<P>21. 19 or 20</P>
<P>22. 4 and 18 and 21</P>
<P>23. random$.tw.</P>
<P>24. factorial$.tw.</P>
<P>25. crossover$.tw.</P>
<P>26. cross over$.tw.</P>
<P>27. cross-over$.tw.</P>
<P>28. placebo$.tw.</P>
<P>29. (doubl$ adj blind$).tw.</P>
<P>30. (singl$ adj blind$).tw.</P>
<P>31. assign$.tw.</P>
<P>32. allocat$.tw.</P>
<P>33. volunteer$.tw.</P>
<P>34. Crossover Procedure/</P>
<P>35. double-blind procedure.tw.</P>
<P>36. Randomized Controlled Trial/</P>
<P>37. Single Blind Procedure/</P>
<P>38. or/23-37</P>
<P>39. (animal/ or nonhuman/) not human/</P>
<P>40. 38 not 39</P>
<P>41. 22 and 40</P>
<P>42. (201109* or 201110* or 201111* or 201112* or 2012* or 2013* or 2014*).dd.</P>
<P>43. 41 and 42</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;In previous versions of review:&lt;/p&gt;&lt;p&gt;2 studies included&lt;/p&gt;&lt;p&gt;9 studies excluded with reasons&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 NEW studies included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 records after duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 records identified through database searching (2011-2015)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;6 records excluded and not related to the review&lt;/p&gt;&lt;p&gt;1 records excluded with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>